

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07K 14/00	A2	(11) International Publication Number: WO 00/20450 (43) International Publication Date: 13 April 2000 (13.04.00)									
<p>(21) International Application Number: PCT/US99/23519</p> <p>(22) International Filing Date: 7 October 1999 (07.10.99)</p> <p>(30) Priority Data:</p> <table border="0"><tr><td>60/103,322</td><td>7 October 1998 (07.10.98)</td><td>US</td></tr><tr><td>60/106,473</td><td>30 October 1998 (30.10.98)</td><td>US</td></tr><tr><td>60/114,088</td><td>29 December 1998 (29.12.98)</td><td>US</td></tr></table> <p>(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): JOHNS, Margaret, Ann [US/US]; 2800 Deake Avenue, Ann Arbor, MI 48108 (US). MOLDOVER, Brian [US/US]; 4893 S. Ridgeside Circle, Ann Arbor, MI 48105 (US). OFFORD, James, David [US/US]; 3388 Alan Mark Drive, Ann Arbor, MI 48105 (US).</p> <p>(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.</p>		60/103,322	7 October 1998 (07.10.98)	US	60/106,473	30 October 1998 (30.10.98)	US	60/114,088	29 December 1998 (29.12.98)	US	<p>(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
60/103,322	7 October 1998 (07.10.98)	US									
60/106,473	30 October 1998 (30.10.98)	US									
60/114,088	29 December 1998 (29.12.98)	US									
(54) Title: ALPHA-2/DELTA GENE											
<p>(57) Abstract</p> <p>The present invention relates to three novel genes and polypeptides derived therefrom encoding "$\alpha 2\delta$-C" and/or "$\alpha 2\delta$-D" proteins which exist as a subunit in many calcium channels. The invention also describes methods for using the novel gene and polypeptides in the detection of genetic deletions of the gene, subcellular localization of the polypeptide, binding assays in connection with chemical databases, gene therapy.</p>											

Express Mail No. EJ881686067US
PD-A0000166-01-CA

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

ALPHA-2/DELTA GENE

FIELD OF THE INVENTION

The present invention relates to novel genes and polypeptides derived and identified therefrom encoding polypeptides related to the alpha-2-delta ("α2δ") protein that is a subunit of the voltage-sensitive calcium channel. In particular, three human novel genes and polypeptides derived and identified therefrom encoding three human polypeptides related to the α2δ protein are disclosed. The invention also describes vectors and host cells comprising the novel genes. The invention also describes methods for using the novel genes, polypeptides, and antibodies specifically targeting the polypeptides in the detection of genetic alterations of the gene, subcellular localization of the polypeptide, gene therapy applications, diagnostics for syndromes associated with altered α2δ expression, such as neurological diseases and disorders, diabetes, cancer, and other diseases associated with α2δ expression, and binding assays in connection with chemical databases, specifically, development of proprietary screening strategies for molecules which modify α2δ protein activity.

BACKGROUND OF THE INVENTION

The voltage activated calcium channels ("VSCCs") of vertebrates have been shown to be involved in a variety of different physiological processes including muscle contraction, insulin release from the pancreas, and neurotransmitter release in the nervous system (Greenberg D. Annals of Neurology, 1997;42:275-82; Catterall W.A., Trends in Neurosciences, 1993;16:500-506; Catterall W., Epstein P.N., Diabetologia, 35(Suppl 2:S23-33) 1992; Birnbaumer L., et al., Neuron, 1994:13; Rorsman P., et al., Diabetes Metab., 1994;20:138-145).

VSCCs are most highly expressed in excitable tissues including brain, skeletal muscle, and heart. They are multiprotein complexes composed of a

-2-

central $\alpha 1$ pore-forming subunit variably associated with beta, gamma, and/or an $\alpha 2\delta$ subunit. Nine different functional classes of VSCCs have been described, based on biophysical and pharmacological studies. These functional classes are mainly determined by the $\alpha 1$ subunit composition. The beta, gamma, and $\alpha 2\delta$ subunits modulate channel function, affecting the kinetics of activation and inactivation, voltage-dependence, peak amplitude, and ligand binding. Walker N., De Waard M., Trends in Neurosciences, 1998;21(4):148-154.

A number of compounds useful in treating various diseases in animals, including humans, are thought to exert their beneficial effects by modulating functions of voltage-dependent calcium channels. Many of these compounds bind to calcium channels and alter cellular calcium flux in response to a depolarizing signal. However, a lack of understanding of the structure of channel subunits and the genes that code for them has hampered scientists both in discerning the pharmacology of compounds that interact with calcium channels and in the ability to rationally design compounds that will interact with calcium channels to have desired therapeutic effects. The lack of understanding is due in part to the fact that it has not been possible to obtain the large amounts of highly purified channel subunits that are required to understand, at the molecular level, the nature of the subunits and their interactions with one another, with the cell membranes across which the channels allow calcium ions to pass, with calcium and other ions, and with low molecular weight compounds that affect channel function.

Further, the lack of information on genes that code for calcium channel subunits has prevented the understanding of the molecular properties of the mature calcium channel subunits and their precursor proteins (i.e., the mature subunits with signal peptides appended to the amino-terminus) and the regulation of expression of calcium channel subunits. An understanding of these properties, and of how expression of calcium channel subunits genes is regulated, may provide the basis for designing therapeutic agents which have beneficial effects through affecting calcium channel function or concentration. Furthermore, the availability of sequences of genes coding for calcium channel subunits would make possible the diagnosis of defects, which might underlie a number of diseases, in genes coding for such subunits.

-3-

Expression experiments in *Xenopus* oocytes have demonstrated that in order to produce fully functional calcium channels, the $\alpha 1$ and $\alpha 2\delta$ subunits must both be expressed. Absence of the $\alpha 2\delta$ subunit results in a nonfunctional channel, even though the $\alpha 1$ subunit, through which ions flow, is fully expressed. Indeed, not only the ion flux through these channels, but the pharmacological properties of the $\alpha 1$ are different in the absence of the $\alpha 2\delta$ subunit. The $\alpha 2\delta$ subunit, therefore, is a critical component of VSCCs and one that must be studied if one is to better characterize VSCC function.

A detailed understanding of VSCC operation is beginning to reveal some mechanisms for interceding in the progression of diseases associated with abnormal VSCC functions. US Patent No. 5,618,720, which issued April 8, 1997, references $\alpha 1$ and $\alpha 2\delta$ subunits and the polynucleotide sequences that encode the subunits. The publication, however, does not disclose any additional $\alpha 2\delta$ subunits and in light of the importance of the $\alpha 2\delta$ subunit, it can be understood that the identification and characterization of new $\alpha 2\delta$ subunits and the genes encoding these subunits would advance molecular genetic and pharmacological studies to understand the relations between the structure and the function of VSCCs.

Also, a further understanding of the biochemical mechanisms behind these subunits and their effect on mammals may lead to new opportunities for treating and diagnosing diseases related to abnormal (high or low) VSCC operation. Stated another way, a better understanding of the molecular mechanisms of VSCC operation will allow improved design of therapeutic drugs that treat diseases related to abnormal VSCC expression, and specifically abnormal $\alpha 2\delta$ expression.

The cDNAs, oligonucleotides, peptides, antibodies for the $\alpha 2\delta$ proteins, which are the subject of this invention, provide a plurality of tools for studying VSCC operations in various cells and tissues and for diagnosing and selecting inhibitors or drugs with the potential to intervene in various disorders or diseases in which altered $\alpha 2\delta$ expression is implicated. Such disease states affected include epilepsy and other seizure-related syndromes, migraine, ataxia and other vestibular defects (for review, Terwindt, GM et. Al., Eur J Hum Genet 1998 Jul-Aug; 6(4):297-307), chronic pain (Backonja M, JAMA 1998 Dec 2;280(21):1831-6), mood, sleep interference (Rowbotham M, JAMA 1998 Dec

-4-

2;280(21):1837-42), anxiety (Singh et al., Psychopharmacology 1996 Sep.
127(1): 1-9), ALS (Mazzini L et. Al., J Neurol Sci 1998 Oct, 160 Suppl 1:S57-
63), multiple sclerosis (Metz L, Semin Neurol 1998;18(3):389-95), mania (Erfurth
A, et al., J Psychiatr Res 1998 Sep-Oct;32(5):261-4), tremor (Evidente VG, et al.,
5 Mov Disord 1998 Sep;13(5):829-31), parkinsonism (Olson WL, et al., Am J Med
1997 Jan;102(1):60-6) substance abuse/addiction syndromes (Watson, WP et al.,
Neuropharmacology 1997 Oct;36(10):1369-75), depression, and cancer, since at
least one $\alpha 2\delta$ gene is located in a region of the genome which is thought to harbor
an important tumor suppressor gene (Kok K., et al., Adv Cancer Res 1997;71:27-
10 92).

The $\alpha 2\delta$ gene is also thought to play a part in proliferative diseases other
than cancer, such as inflammation. Treatment with compounds which bind to
 $\alpha 2\delta$ lead to changes in the signal transduction mechanism of certain proteins.
This includes altered levels of MEK (eg, MEK1 and MEK2) which activates the
15 MAP kinase. Inhibitors of MEK appear to mimic the analgesic activities
associated with the binding of gabapentin to $\alpha 2\delta$. Activation of MAP kinase by
mitogens appears to be essential for proliferation, and constitutive activation of
this kinase is sufficient to induce cellular transformation.

20 SUMMARY OF THE INVENTION

While the $\alpha 1$ subunit is known to be coded for by 9 genes, the beta subunit
by 4 genes, and the gamma subunit by 2 genes, previously only two human $\alpha 2\delta$
genes were known: " $\alpha 2\delta$ -A (cDNA Accession No. M76559.1 and protein
Accession No. P54289.1) and $\alpha 2\delta$ -B (cDNA SEQ ID NO 1 and protein SEQ ID
25 NO 2). The $\alpha 2\delta$ -A gene codes for at least five different splice variants which
show tissue-specific expression (Angelotti T., Hoffman F., FEBS, 1996;397:331-
337). Translation of the $\alpha 2\delta$ -A gene produces a polypeptide which is post-
translationally cleaved into the $\alpha 2$ and the δ subunits. $\alpha 2$ and δ are then joined by
disulfide bonds (De Jongh K., JBC, 1990;265(25):14738-14741; Jay S., JBC,
30 1991;266(5):3287-3293). $\alpha 2$ is thought to be completely extracellular and is
heavily glycosylated, while δ probably forms a single transmembrane domain
with five intracellular amino acids at its c-terminus (Brickley K., FEBS,

-5-

1995;364:129-133). This transmembrane domain anchors the protein to the membrane. A2 δ -B is related to α 2 δ -A and is available in the public database, GENBANK.

5 The inventors, however, have discovered the existence of two new human α 2 δ genes, hereinafter referred to as " α 2 δ -C", and " α 2 δ -D" genes (gene names CACNA2C and CACNA2D). The present invention, therefore, relates to the isolation of polynucleotide sequences which identify and encode novel α 2 δ -related proteins (preferably α 2 δ -C and α 2 δ -D proteins) that are expressed in various cells and tissues, both the polynucleotide sequences for the full length
10 genes and any splice variants and their encoded proteins. The polynucleotide sequences are identified in SEQ ID NOS 3-4 and the amino acid sequences of the α 2 δ proteins encoded by the three novel genes are set forth in SEQ ID NOS 5-6.

The invention also concerns a purified or isolated nucleic acid comprising at least 20 consecutive nucleotides of the nucleotide sequences SEQ ID NOS 3-4,
15 or a nucleotide sequence complementary thereto.

A2 δ -C protein of SEQ ID NO 5 is 28% identical and 48% similar at the protein level to α 2 δ -A protein. A2 δ -C protein is 28% identical and 47% similar to α 2 δ -B. A2 δ -C gene of SEQ ID NO 3 contains a mapped marker (known as an STS) within its nucleotide sequence which has been mapped to human
20 chromosome 3p21.1. This region of the human genome is thought to harbor an important tumor suppressor gene, thus α 2 δ -C gene is a candidate tumor suppressor gene (Kersemaekers AM, et al., Br J Cancer 1998;77(2); 192-200).

A2 δ -D protein of SEQ ID NO 6 is 28% identical and 47% similar at the protein level to α 2 δ -A protein. A2 δ -D protein is 28% identical and 46% similar
25 to α 2 δ -B protein. A2 δ -D gene of SEQ ID 4 maps to a previously published cosmid contig on human chromosome 12p13.3.

The unique full length polynucleotides of the present invention were initially discovered by mining the genbank database for sequences with homology to α 2 δ , by utilizing known nucleotide sequences and various methods known in
30 the art, including tools provided by Compugen Systems Ltd. See Sequence Analysis Primer by Michael Gribskov, John Devereux, Oxford University Press, 1994. After identification of expressed sequenced tags (ESTs) and full-length

-6-

sequences related to $\alpha 2\delta$ -A, cloning methods were used to obtain, in hand, full-length sequences for $\alpha 2\delta$ -C and $\alpha 2\delta$ -D, see Examples 1, 2 and 3. In short, an arrayed human, kidney cDNA library obtained from Origene, was screened by PCR, using oligonucleotide primers derived from the database sequences. Clones identified from the library screen were sequenced by standard methods for verification. A summary of the sequencing information is provided in Example 3.

Analysis of the cloned sequences for $\alpha 2\delta$ -B, $\alpha 2\delta$ -C, and $\alpha 2\delta$ -D led to the identification of a conserved domain and of a number of splice variants. The conserved domain is known as a vonWillebrand factor A3 domain (Huizinga, EG, et. al., Structure 1997, Sept 15;5(9):1147-56). This domain has been described in a large number of proteins and is thought to mediate cell adhesion. Interesting splice-variants of $\alpha 2\delta$ -C and $\alpha 2\delta$ -D were also identified. These variants result in a c-terminal truncation of the respective protein sequences. Truncation of the c-terminus may lead to the production of a soluble, secreted $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein with new functions beyond that previously described for $\alpha 2\delta$.

The $\alpha 2\delta$ proteins are of interest because they play an important role in many disease states. In one example, $\alpha 2\delta$ -A has been shown to be a high-affinity binding target of the anti-convulsant drug gabapentin (NEURONTIN) (Gee N., JBC 1996;271:5768-5776). This property of the $\alpha 2\delta$ -A protein has the potential to have profound physiological effects. Thus, by regulating the levels or activities of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, or by modulating their function, desirable physiological effects may be obtained. Such effects may be used to treat a variety of diseases involving abnormal expression of $\alpha 2\delta$ or the abnormal expression of VSCCs (i.e., disease states include, but are not limited to epilepsy, chronic pain, anxiety, diabetes, ALS, mania, cancer, tremor, parkinsonism, migraine, ataxia, mood, sleep interference, depression, multiple sclerosis, inflammation).

The rationale for the therapeutic use of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins to design or discover treatment for these diseases is based upon the fact that gabapentin has been successfully used for treating epilepsy, chronic pain, and ALS, and has implications for use in the treatment of mania, tremor, parkinsonism, migraine, ataxia, mood, inflammation, sleep interference, and/or multiple sclerosis). Gabapentin is known to bind to $\alpha 2\delta$ -A with high affinity and

-7-

this binding is thought to represent the mechanism of action of gabapentin.

Therefore, gabapentin and/or other compounds which bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins may have similar, or related, therapeutic effects to the effects seen with gabapentin. Also, compounds which are known to have therapeutic effects on calcium channels are regulated in their affinity by the presence of $\alpha 2\delta$. Thus, pharmacological or genetic approaches to alleviating this deficiency will have a major impact on the diseases described above.

One aspect of the invention is to provide purified $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The purified proteins may be obtained from either recombinant cells or naturally occurring cells. The purified $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the invention may be mammalian in origin. Primate, including human-derived $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, are examples of the various proteins specifically provided for. The invention also provides allelic variants and biologically active derivatives of naturally occurring $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins.

Another aspect of the invention is to provide polynucleotides encoding the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the invention and to provide polynucleotides complementary to polynucleotide coding strand. The polynucleotides of the invention may be used to provide for the recombinant expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The polynucleotides of the invention may also be used for genetic therapy purposes so as to 1) treat diseases which may result from alterations of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes or from alterations of cellular pathways involving $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, 2) test for presence of a disease, or susceptibility to a disease, due to alterations or deletions in $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, 3) analyze or alter the subcellular localization of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D polypeptide, 4) clone or isolate discrete classes of RNA similar to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes, 5) express discrete classes of RNA in order to alter the levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes.

The invention also relates to oligonucleotide molecules useful as probes or primers, wherein said oligonucleotide molecules hybridize specifically with any nucleotide sequence comprising or related to the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes, particularly the sequences of SEQ ID NOS 3-4. These oligonucleotides are useful

-8-

either as primers for use in various processes such as DNA amplification and microsequencing or as probes for DNA recognition in hybridization analyses.

A nucleic acid probe or primer according to the invention comprises at least 8 consecutive nucleotides of a polynucleotide of SEQ ID NOS 3-4,
5 preferably from 8 to 200 consecutive nucleotides, more particularly from 10, 15, 20 or 30 to 100 consecutive nucleotides, more preferably from 10 to 90 nucleotides, and most preferably from 20 to 80 consecutive nucleotides of a polynucleotide of SEQ ID NOS 3 or 4. Preferred probes or primers of the invention comprise the oligonucleotides selected from the group consisting of the
10 oligonucleotides set forth in the examples below.

The invention also concerns a method for the amplification of a region of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes. The method comprises the step of:
contacting a test sample suspected of containing the desired $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D
sequence or portion thereof with amplification reaction reagents, comprising a
15 pair of amplification primers such as those described above, the primers being located on either side of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D nucleotide region to be amplified. The method may further comprise the step of detecting the amplification product. For example, the amplification product may be detected using a detection probe that can hybridize with an internal region of the amplified
20 sequences. Alternatively, the amplification product may be detected with any of the primers used for the amplification reaction themselves, optionally in a labeled form.

The invention also concerns diagnostic kits for detecting the presence of at least one copy of a $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D DNA in a test sample, said kits
25 containing a primer, a pair of primers or a probe according to the invention.

In a first embodiment, the kit comprises primers such as those described above, preferably forward and reverse primers which are used to amplify the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene or a fragment thereof.

In a second embodiment, the kit comprises a hybridization DNA probe,
30 that is or eventually becomes immobilized on a solid support, which is capable of hybridizing with the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene or a fragment thereof. The

-9-

techniques for immobilizing a nucleotide primer or probe on a solid support are well-known to the skilled person.

The kits of the present invention can also comprise optional elements including appropriate amplification reagents such as DNA polymerases when the kit comprises primers, reagents useful in hybridization reactions and reagents
5 useful to reveal the presence of a hybridization reaction between a labeled hybridization probe and the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene.

Another aspect of the invention is to provide antibodies capable of binding to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the invention. The antibodies may be
10 polyclonal or monoclonal. The invention also provides methods of using the subject antibodies to detect and measure expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins either *in vitro* or *in vivo*, or for detecting proteins that interact with $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, or molecules that regulate any of the activities of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins.

Another aspect of the invention is to provide assays for the detection of
15 proteins that interact with $\alpha 2\delta$ -C or $\alpha 2\delta$ -D using genetic approaches. A preferred embodiment involves the use of yeast two-hybrid approaches for this screening. (Bartel and Fields, The Yeast Two-Hybrid System, Oxford University Press, 1997)

Another aspect of the invention is to provide assays for the detection or
20 screening of therapeutic compounds that interfere with, or mimic in any way, the interaction between $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins and ligands that bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins.

In a first embodiment, such a method for the screening of a candidate
25 substance comprises the following steps :

- a) providing a polypeptide comprising the amino acid sequence of SEQ ID NO 5 and/or 6, or a peptide fragment or a variant thereof;
- b) obtaining a candidate substance;
- c) bringing into contact said polypeptide with said candidate substance; and
- 30 d) detecting the complexes formed between said polypeptide and said candidate substance.

-10-

In one embodiment of the screening method defined above, the complexes formed between the polypeptide and the candidate substance are further incubated in the presence of a polyclonal or a monoclonal antibody that specifically binds to the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein of the invention or to the peptide fragment or variant thereof.

The candidate substance or molecule to be assayed for interacting with the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D polypeptide may be of diverse nature, including, without being limited to, natural or synthetic organic compounds or molecules of biological origin such as polypeptides.

In another embodiment of the present screening method, increasing concentrations of a substance competing for binding to the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein with the considered candidate substance is added, simultaneously or prior to the addition of the candidate substance or molecule, when performing step c) of said method. By this technique, the detection and optionally the quantification of the complexes formed between the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or the peptide fragment or variant thereof and the candidate substance or molecule to be screened allows the one skilled in the art to determine the affinity value of said substance or molecule for said $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or the peptide fragment or variant thereof.

The invention also pertains to kits useful for performing the hereinbefore described screening method. Preferably, such kits comprise a $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein having the amino acid sequence of SEQ ID NO 5 and/or 6 or a peptide fragment or a variant thereof, and optionally means useful to detect the complex formed between the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or its peptide fragment or variant and the candidate substance. In a preferred embodiment the detection means consist in monoclonal or polyclonal antibodies directed against the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or a peptide fragment or a variant thereof.

The assays of the invention therefore comprise the step of measuring the effect of a compound of interest on binding between $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and the ligands that bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. Binding may be measured in a variety of ways, including the use of labeled $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or labeled ligands. These ligands may include, but are not limited to,

-11-

neutral alpha-amino acids, which have been shown to bind to $\alpha 2\delta$ -A, or therapeutic compounds such as gabapentin or related analogues.

Another aspect of the invention is to provide assays for the discovery of proteins that interact directly or indirectly with $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The assays of the invention comprise a method for detecting such interactions in cells, or in biochemical assays. These interactions may be detected in a variety of ways, including the use of the cDNA encoding $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, or $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins themselves, or fragments or modifications thereof. The assays may also comprise a method for detecting the interaction between $\alpha 2\delta$ subunits and other subunits of the calcium channel, such as $\alpha 1$ subunits. These assays may involve measuring the interaction between the proteins directly, or assaying the activity of a fully assembled calcium channel.

Before the present sequences, polypeptides, methods for making and using the invention are described, it is to be understood that the invention is not to be limited only to the particular sequences, polypeptides and methods described. The sequences, polypeptides and methodologies may vary, and the terminology used herein is for the purpose of describing particular embodiments. The foregoing is not intended and should not be construed as limiting the invention in any way since the scope of protection will ultimately depend upon the claims. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All U.S. patents and all publications mentioned herein are incorporated in their entirety by reference thereto.

BRIEF DESCRIPTION OF THE INVENTION

- Figure 1: Fine-mapping of $\alpha 2\delta$ -B to mouse chromosome 9
- Figure 2: Human $\alpha 2\delta$ -B tissue distribution
- Figure 3: [3 H] gabapentin binding activity by human $\alpha 2\delta$ -B in transiently transfected COS7
- Figure 4: Human $\alpha 2\delta$ -C tissue distribution

-12-

DETAILED DESCRIPTION OF THE INVENTION

Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: *Molecular Cloning: A Laboratory Manual* (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), *Gene Expression Technology* (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, CA), "Guide to Protein Purification" in *Methods in Enzymology* (M.P. Deutscher, ed., (1990) Academic Press, Inc.); *PCR Protocols: A Guide to Methods and Applications* (Innis, et al. 1990. Academic Press, San Diego, CA), *Culture of Animal Cells: A Manual of Basic Technique, 2nd Ed.* (R.I. Freshney. 1987. Liss, Inc. New York, NY), and *Gene Transfer and Expression Protocols*, pp. 109-128, ed. E.J. Murray, The Humana Press Inc., Clifton, N.J.) *Sequence Analysis Primer* (Gribskov, et al., 1994, Oxford University Press).

In one aspect, the present invention provides novel isolated and purified polynucleotides, hereinafter referred to as $\alpha 2\delta$ -C and $\alpha 2\delta$ -D (" $\alpha 2\delta$ -C", " $\alpha 2\delta$ -D") genes, encoding $\alpha 2\delta$ -C and $\alpha 2\delta$ -D proteins, wherein the polynucleotide sequences are substantially similar to those shown in SEQ ID NOS 3-4 and the polypeptide sequences are substantially similar to those shown in SEQ ID NOS 5-6. The terms " $\alpha 2\delta$ -C" and " $\alpha 2\delta$ -D" are used broadly herein. Unless noted otherwise, the terms " $\alpha 2\delta$ -C" and " $\alpha 2\delta$ -D" include any natural mammalian-derived form of $\alpha 2\delta$ -C and $\alpha 2\delta$ -D and the like. It is preferred that the terms $\alpha 2\delta$ -C and $\alpha 2\delta$ -D include all mammals, including but not limited to primates and humans.

The polynucleotides provided for may encode complete $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins or portions thereof. The polynucleotides of the invention may be produced by a variety of methods including *in vitro* chemical synthesis using well known solid phase synthesis technique, by cloning or combinations thereof. The polynucleotide of the invention may be derived from cDNA or genomic libraries. Persons of ordinary skill in the art are familiar with the degeneracy of the genetic code and may readily design polynucleotides that encode $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins that have either partial or polynucleotide sequence homology to naturally

-13-

occurring polynucleotide sequences encoding $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. The polynucleotides of the invention may be single stranded or double stranded. Polynucleotide complementary to polynucleotides encoding $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins are also provided.

5 Polynucleotides encoding an $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein can be obtained from cDNA libraries prepared from tissue believed to possess $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or mRNA and to express it at a detectable level. For example, a cDNA library can be constructed by obtaining polyadenylated mRNA from a cell line known to express $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, and using the mRNA as a
10 template to synthesize double stranded cDNA.

Libraries, either cDNA or genomic, are screened with probes designed to identify the gene of interest or the protein encoded by it. For cDNA expression libraries, suitable probes include monoclonal and polyclonal antibodies that recognize and specifically bind to an $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein. For cDNA
15 libraries, suitable probes include carefully selected oligonucleotide probes (usually of about 20-80 bases in length) that encode known or suspected portions of an $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein from the same or different species, and/or complementary or homologous cDNAs or fragments thereof that encode the same or a similar gene, and/or homologous genomic DNAs or fragments thereof.
20 Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures as described in Chapters 10-12 of Sambrook et al., Molecular Cloning: A Laboratory Manual, New York, Cold Spring Harbor Laboratory Press, 1989).

A preferred method of practicing this invention is to use carefully selected
25 oligonucleotide sequences to screen cDNA libraries from various tissues. The oligonucleotide sequences selected as probes should be sufficient in length and sufficiently unambiguous that false positives are minimized. The actual nucleotide sequence(s) is/are usually designed based on regions of an $\alpha 2\delta$ protein that have the least codon redundancy. The oligonucleotides may be degenerate at
30 one or more positions. The use of degenerate oligonucleotides is of particular importance where a library is screened from a species in which preferential codon usage is not known.

-14-

The oligonucleotide must be labeled such that it can be detected upon hybridization to DNA in the library being screened. The preferred method of labeling is to use ATP (e.g., T32P) and polynucleotide kinase to radiolabel the 5' end of the oligonucleotide. However, other methods may be used to label the oligonucleotide, including, but not limited to, biotinylation or enzyme labeling.

cDNAs encoding $\alpha 2\delta$ proteins can also be identified and isolated by other known techniques of recombinant DNA technology, such as by direct expression cloning or by using the polymerase chain reaction (PCR) as described in U.S. Patent No. 4,683,195, in section 14 of Sambrook, et al. , Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press, New York, 1989, or in Chapter 15 of Current Protocols in Molecular Biology, Ausubel et al. eds., Green Publishing Associates and Wiley-Interscience 1991. This method requires the use of oligonucleotide probes that will hybridize to DNA encoding an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein.

As defined herein, "substantially similar" includes identical sequences, as well as deletions, substitutions or additions to a DNA, RNA or protein sequence that maintain any biologically active portion thereof of the protein product and possess any of the conserved motifs. This includes, but is not limited to, any splice variants of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D which are found to exist. Preferably, the DNA sequences according to the invention consist essentially of the DNA sequence of SEQ ID NOS 3-4. These novel purified and isolated DNA sequences can be used to direct expression of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and for mutational analysis of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein function.

Mutated sequences according to the invention can be identified in a routine manner by those skilled in the art using the teachings provided herein, and techniques well known in the art.

In a preferred embodiment, the present invention comprises a nucleotide sequence that hybridizes to the nucleotide sequence shown in SEQ ID NOS 3-4 under high stringency hybridization conditions. As used herein, the term "high stringency hybridization conditions" refers to hybridization on a filter support at 65°C in a low salt hybridization buffer to the probe of interest at 2×10^8 cpm/ μ g for between about 8 hours to 24 hours, followed by washing in 1% SDS, 20 mM

-15-

phosphate buffer and 1 mM EDTA at 65°C, for between about 30 minutes to 4 hours. In a preferred embodiment, the low salt hybridization buffer comprises between, 0.5-10% SDS, and 0.05M and 0.5 M sodium phosphate. In a most preferred embodiment, the low salt hybridization buffer comprises, 7% SDS, and 0.125M sodium phosphate.

As known in the art, numerous equivalent conditions may be employed to comprise either low or high stringency conditions. Factors such as the length and nature (DNA, RNA, base composition) of the sequence, nature of the target (DNA, RNA, base composition, presence in solution or immobilization, etc.), and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate and/or polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

The term "stringent conditions", as used herein, is the "stringency" which occurs within a range from about $T_m - 5^\circ\text{C}$ (5°C below the melting temperature (T_m) of the probe) to about 20°C to 25°C below T_m . As will be understood by those of skill in the art, the stringency of hybridization may be altered in order to identify or detect identical or related polynucleotide sequences.

The polynucleotides of the invention have a variety of uses, some of which have been indicated or will be addressed in greater detail, *infra*. The particular uses for a given polynucleotide depend, in part, on the specific polynucleotide embodiment of interest. The polynucleotides of the invention may be used as hybridization probes to recover $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins from genetic libraries. The polynucleotides of the invention may also be used as primers for the amplification of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein encoding polynucleotides or a portion thereof through the polymerase chain reaction (PCR) and other similar amplification procedures. The polynucleotides of the invention may also be used as probes and amplification primers to detect mutations in $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein encoding genes that have been correlated with diseases, particularly diseases related to an altered function for $\alpha 2\delta$ -A protein. Including, but not limited to, those diseases stated above.

-16-

The invention also provides a variety of polynucleotide expression vectors, comprising $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, or a sequence substantially similar to it subcloned into an extra-chromosomal vector. This aspect of the invention allows for *in vitro* expression of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene, thus permitting an analysis of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene regulation and $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein structure and function. As used herein, the term "extra-chromosomal vector" includes, but is not limited to, plasmids, bacteriophages, cosmids, retroviruses and artificial chromosomes. In a preferred embodiment, the extra-chromosomal vector comprises an expression vector that allows for $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein production when the recombinant DNA molecule is inserted into a host cell. Such vectors are well known in the art and include, but are not limited to, those with the T3 or T7 polymerase promoters, the SV40 promoter, the CMV promoter, or any promoter that either can direct gene expression, or that one wishes to test for the ability to direct gene expression.

In a preferred embodiment, the subject expression vectors comprise a polynucleotide sequence encoding an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein in functional combination with one or more promoter sequences so as to provide for the expression of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein (or an anti-sense copy of the sequence suitable for inhibition of expression of an endogenous gene). The vectors may comprise additional polynucleotide sequences for gene expression, regulation, or the convenient manipulation of the vector, such additional sequences include terminators, reporters, enhancers, selective markers, packaging sites, and the like. Detailed description of polynucleotide expression vectors and their use can be found in, among other places Gene Expression Technology: Methods in Enzymology Volume 185 Goeddel ed, Academic Press Inc., San Diego, CA (1991), Protein Expression in Animal Cells Roth et al., Academic Press, San Diego, CA (1994).

The polynucleotide expression vectors of the invention have a variety of uses. Such uses include the genetic engineering of host cells to express $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. In a further aspect, the present invention provides recombinant host cells that are stably transfected with a recombinant DNA molecule comprising $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D subcloned into an extra-chromosomal

-17-

vector. The host cells of the present invention may be of any type, including, but not limited to, bacterial, yeast, mammalian cells, and *Xenopus* oocytes.

Transfection of host cells with recombinant DNA molecules is well known in the art (Sambrook et al., *Molecular Cloning, A Laboratory Manual*, 2nd ed., Cold Spring Harbor Press, 1989) and, as used herein, includes, but is not limited to
5 calcium phosphate transfection, dextran sulfate transfection, electroporation, lipofection and viral infection. This aspect of the invention allows for *in vitro* and *in vivo* expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D and its gene product, thus enabling high-level expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. In a further aspect of the
10 invention the RNA molecules containing $\alpha 2\delta$ -C or $\alpha 2\delta$ -D can be injected into *Xenopus* oocytes along with other calcium channel subunit clones and calcium flux across the oocyte membrane can be measured using standard electrophysiological techniques.

In another aspect of the invention transgenic animals can be constructed by
15 injection of the nucleotide sequence for $\alpha 2\delta$ -C or $\alpha 2\delta$ -D cloned in suitable expression vectors into germ cells.

Other uses of the polynucleotide expression vectors, discussed in greater detail, *infra*, include, their use for genetic therapy for diseases and conditions in which it may be desirable use to express $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins at levels
20 greater than naturally occurring expression levels. Alternatively, it may be desirable to use the subject vectors for anti-sense expression to reduce the naturally occurring levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein.

$\alpha 2\delta$ -C and $\alpha 2\delta$ -D share amino acid homology to $\alpha 2\delta$ -A, thus it is very likely that they share some structural and functional characteristics with $\alpha 2\delta$ -A.
25 $\alpha 2\delta$ -A is known to interact with other subunits of voltage-sensitive calcium channels, such as $\alpha 1$ and beta. When calcium channels are expressed in oocytes, a functional channel is only produced when an $\alpha 2\delta$ subunit is present. Therefore, $\alpha 2\delta$ is required for calcium channel function. In addition, $\alpha 2\delta$ -A has been shown to bind to gabapentin, a drug used to treat epilepsy, chronic pain, ALS, and
30 potentially other neurological diseases. The mechanism of action of gabapentin is thought to be through its interaction with $\alpha 2\delta$. Given the homology between the $\alpha 2\delta$ proteins, it is likely that $\alpha 2\delta$ -C and $\alpha 2\delta$ -D also share these functions.

-18-

The polynucleotide sequences of SEQ ID NOS 3-4 were mapped to human chromosomes using the nucleotide sequences for the cDNA from library sources (See Examples 2-3) to generate probes. The sequences were mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. These include in situ hybridization to chromosomal spreads, and PCR-based mapping by amplifying DNA from standard radiation hybrid cell lines. (Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, NYC. A2 δ -C of SEQ ID NO 3 maps to human chromosome 3p21.1. A2 δ -D of SEQ ID NO 4 maps to a previously published cosmid contig on human chromosome 12p13.3.

In another aspect, the present invention provides a substantially purified recombinant protein comprising a polypeptide substantially similar to the α 2 δ -C and/or α 2 δ -D polypeptides shown in SEQ ID NOS 5-6. Furthermore, this aspect of the invention enables the use of α 2 δ protein in several *in vitro* assays described below. As used herein, the term "substantially similar" includes deletions, substitutions and additions to the sequences of SEQ ID NOS 5-6 introduced by any *in vitro* means, or any genetic alterations naturally seen *in vivo*. As used herein, the term "substantially purified" means that the protein should be free from detectable contaminating protein, but the α 2 δ -C and/or α 2 δ -D protein may be co-purified with an interacting protein, or as an oligomer. In a most preferred embodiment, the protein sequence according to the invention comprises an amino acid sequence of SEQ ID NOS 5-6. Mutated sequences according to the invention can be identified in a routine manner by those skilled in the art using the teachings provided herein and techniques well known in the art. This aspect of the invention provides a novel purified protein that can be used for *in vitro* assays, and as a component of a pharmaceutical composition.

A2 δ -C and/or α 2 δ -D proteins may be used to discover molecules that interfere with its activities. For example, molecules that prevent the binding of α 2 δ -C and/or α 2 δ -D to ligands such as neutral alpha-amino acids (for example (L)-leucine), or to other molecules such as other subunits of the voltage-sensitive calcium channels.. Additionally, α 2 δ -C and/or α 2 δ -D proteins may be used to

-19-

find other proteins with which it directly interacts, and potentially representing additional important regulators of VSCC transport.

The $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins of the present invention have a putative biological activity of modulating the cellular flux of calcium, potentially including both intracellular and extracellular calcium stores. The $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein of the invention may be isolated from a variety of mammalian animal species. Preferred mammalian species for isolation are primates and humans. The invention also contemplates allelic variants of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins may be prepared from a variety of mammalian tissues. Preferably, $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins are obtained from recombinant host cells genetically engineered to express significant quantities of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins may be isolated from non-recombinant or recombinant cells in a variety of ways well known to a person of ordinary skill in the art.

The terms " $\alpha 2\delta$ -C protein" and " $\alpha 2\delta$ -D protein" as used herein refers not only to proteins having the amino acid residue sequence of naturally occurring $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins, but also refers to functional derivatives and variants of naturally occurring $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. A "functional derivative" of a native polypeptide is a compound having a qualitative biological activity in common with the native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. Thus, a functional derivative of a native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein is a compound that has a qualitative biological activity in common with a native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, e.g., binding to other calcium channel subunits and modulating the flux of calcium in cells, or binding to neutral alpha-amino acids and other cognate ligands. "Functional derivatives" include, but are not limited to, fragments of native polypeptides from any animal species (including human), and derivatives of native (human and non-human) polypeptides and their fragments, provided that they have a biological activity in common with a respective native polypeptide. "Fragments" comprise regions within the sequence of a mature native polypeptide. The term "derivative" is used to define amino acid sequence and glycosylation variants, and covalent modifications of a native polypeptide, whereas the term "variant" refers to amino acid sequence and glycosylation

-20-

variants within this definition. Preferably, the functional derivatives are polypeptides which have at least about 70% amino acid sequence similarity, more preferably about 80% amino acid sequence similarity, even more preferably at least 90% amino acid sequence similarity, most preferably at least about 99% amino acid sequence similarity with the sequence of a corresponding native polypeptide. Most preferably, the functional derivatives of a native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein retain or mimic the region or regions within the native polypeptide sequence that directly participate in ligand binding. The phrase "functional derivative" specifically includes peptides and small organic molecules having a qualitative biological activity in common with a native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein.

"Identity" or "homology" with respect to a native polypeptide and its functional derivative is defined herein as the percentage of amino acid residues in the candidate sequence that are similar to residues of a corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. Neither N- or C-terminal extensions nor insertions, nor alternatively-spliced variants, shall be construed as reducing identity or homology. Methods and computer programs for the alignment are well known in the art.

Amino acid sequence variants of native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins and $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein fragments are prepared by methods known in the art by introducing appropriate nucleotide changes into a native or variant $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein encoding DNA, or by *in vitro* synthesis of the desired polypeptide. There are two principal variables in the construction of amino acid sequence variants: the location of the mutation site and the nature of the mutation. With the exception of naturally-occurring alleles, which do not require the manipulation of the DNA sequence encoding the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, the amino acid sequence variants of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein are preferably constructed by mutating the DNA, either to arrive at an allele or an amino acid sequence variant that does not occur in nature.

-21-

Alternatively or in addition, amino acid alterations can be made at sites that differ in $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins from various species, or in highly conserved regions, depending on the goal to be achieved.

Sites at such locations will typically be modified in series, e.g. by

- 5 (1) substituting first with conservative choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue or residues, or (3) inserting residues of the same or different class adjacent to the located site, or combinations of options 1-3.

One helpful technique is called "alanine scanning" Cunningham and Wells, Science 244, 1081-1085 (1989). Here, a residue or group of target residues is identified and substituted by alanine or polyalanine. Those domains demonstrating functional sensitivity to the alanine substitutions are then refined by introducing further or other substituents at or for the sites of alanine substitution.

15 After identifying the desired mutation(s), the gene encoding an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein variant can, for example, be obtained by chemical synthesis.

More preferably, DNA encoding an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein amino acid sequence variant is prepared by site-directed mutagenesis of DNA that encodes an earlier prepared variant or a nonvariant version of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. Site-directed (site-specific) mutagenesis allows the production of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein variants through the use of specific oligonucleotide sequences that encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 20 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered. In general, the techniques of site-specific mutagenesis are well known in the art, as exemplified by publications such as, Edelman et al., DNA 2:183 (1983). As will be appreciated, the site-specific mutagenesis technique typically employs a phage vector that exists in both a single-stranded and double-stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. This and other phage vectors are commercially available and their use is well known to those skilled in the art.

-22-

A versatile and efficient procedure for the construction of oligodeoxyribonucleotide directed site-specific mutations in DNA fragments using M13-derived vectors was published by Zoller, M.J. and Smith, M., *Nucleic Acids Res.* 10, 6487-6500 [1982]). Also, plasmid vectors that contain a single-stranded phage origin of replication, Veira et al., *Meth. Enzymol.* 153:3 (1987)] may be employed to obtain single-stranded DNA. Alternatively, nucleotide substitutions are introduced by synthesizing the appropriate DNA fragment in vitro, and amplifying it by PCR procedures known in the art.

In general, site-specific mutagenesis may be performed by obtaining either a double-stranded or a single-stranded vector that includes within its sequence a DNA sequence that encodes the relevant protein. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically, for example, by the method of Crea et al., Proc. Natl. Acad. Sci. USA 75, 5765 (1978). This primer is then annealed with the single-stranded protein sequence-containing vector, and subjected to DNA-polymerizing enzymes such as, *E. coli* polymerase I Klenow fragment, to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate host cells such as HB101 cells, and clones are selected that include recombinant vectors bearing the mutated sequence arrangement. Thereafter, the mutated region may be removed and placed in an appropriate expression vector for protein production.

The PCR technique may also be used in creating amino acid sequence variants of an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. When small amounts of template DNA are used as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template. For introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation; the sequence of the other primer must be identical to a stretch of sequence of the

-23-

opposite strand of the plasmid, but this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 500-5000 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primes can be easily
5 sequenced. PCR amplification using a primer pair like the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.

Further details of the foregoing and similar mutagenesis techniques are
10 found in general textbooks, such as, for example, Sambrook et al., Molecular Cloning: H Laboratory Manual 2nd edition, Cold Spring Harbor Press, Cold Spring Harbor (1989), and Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley and Sons (1995).

Naturally-occurring amino acids are divided into groups based on common
15 side chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophobic: cys, ser, tier;
- (3) acidic: asp, glu;
- 20 (4) basic: asn, gin, his, lys, erg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, pine.

Conservative substitutions involve exchanging a member within one group
25 for another member within the same group, whereas non-conservative substitutions will entail exchanging a member of one of these classes for another. Variants obtained by non-conservative substitutions are expected to result in significant changes in the biological properties/function of the obtained variant, and may result in $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein variants which block $\alpha 2\delta$ -C and/or
30 $\alpha 2\delta$ -D protein biological activities, i.e., modulation of calcium flux, or binding to neutral, alpha-amino acids. Amino acid positions that are conserved among

-24-

various species are generally substituted in a relatively conservative manner if the goal is to retain biological function.

Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably about 1 to 10 residues, and typically are contiguous. Deletions may be introduced into regions not directly involved in ligand binding.

Amino acid insertions include amino- and/or carboxyl terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions (i.e. insertions within the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein amino acid sequence) may range generally from about 1 to 10 residues, more preferably 1 to 5 residues, more preferably 1 to 3 residues. Examples of terminal insertions include the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins with an N-terminal methionyl residue, a naturally-occurring N-terminal signal sequence, an artifact of direct expression in bacterial recombinant cell culture, and fusion of a heterologous N-terminal signal sequence to the N-terminus of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein to facilitate the secretion of the mature $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein from recombinant host cells. Such signal sequences will generally be obtained from, and thus homologous to, the intended host cell species. Suitable sequences include STII or Ipp for *E. coli*, alpha factor for yeast, and viral signals such as herpes gD for mammalian cells. Other insertional variants of the native $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein molecules include the fusion of the N- or C-terminus of an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein to immunogenic polypeptides, e.g. bacterial polypeptides such as betalactamase or an enzyme encoded by the *E. coli* trp locus, or yeast protein, and C-terminal fusions with proteins having a long half-life such as immunoglobulin regions (preferably immunoglobulin constant regions), albumin, or ferritin, as described in PCT published application WO 89/02922.

Since it is often difficult to predict in advance the characteristics of a variant $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, it will be appreciated that screening will be needed to select the optimum variant. For this purpose biochemical screening assays, such as those described herein below, will be readily available.

In a further aspect, the present invention provides antibodies and methods

-25-

for detecting antibodies that selectively bind polypeptides with an amino acid sequence substantially similar to the amino acid sequence of SEQ ID NOS 5-6. As discussed in greater detail, *infra*, the antibody of the present invention can be a polyclonal or a monoclonal antibody, prepared by using all or part of the sequence of SEQ ID NOS 5-6, or modified portions thereof, to elicit an immune response in a host animal according to standard techniques (Harlow and Lane (1988), eds. Antibody: A Laboratory Manual, Cold Spring Harbor Press). In a preferred embodiment, the entire polypeptide sequence of SEQ ID NOS 5-6 is used to elicit the production of polyclonal antibodies in a host animal.

The method of detecting $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D antibodies comprises contacting cells with an antibody that recognizes $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and incubating the cells in a manner that allows for detection of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein-antibody complex. Standard conditions for antibody detection of antigen can be used to accomplish this aspect of the invention (Harlow and Lane, 1988). This aspect of the invention permits the detection of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein both *in vitro* and *in vivo*.

The subject invention provides methods for the treatment of a variety of diseases characterized by undesirably abnormal cellular levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D. Diseases may be treated through either *in vivo* or *in vitro* genetic therapy. Protocols for genetic therapy through the use of viral vectors can be found, among other places, in Viral Vector Gene Therapy and Neuroscience Applications, Kaplit and Lowry, Academic Press, San Diego (1995). Gene therapy applications typically involve identifying target host cells or tissues in need of the therapy, designing vector constructs capable of expressing a desired gene product in the identified cells, and delivering the constructs to the cells in a manner that results in efficient transduction of the target cells. The cells or tissues targeted by gene therapy are typically those that are affected by the disease that the vector construct is designed to treat. For example, in the case of cancer, the targeted tissues are malignant tumors.

The genetic therapy methods of the present invention comprise the step of introducing a vector for the expression of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein (or inhibitory anti-sense RNA) into a patient cell. The patient cell may be either in

-26-

the patient, i.e., *in vivo* genetic therapy, or external to the patient and subsequently reintroduced into the patient, i.e., *in vitro* genetic therapy. Diseases that may be treated by the subject genetic therapy methods include, but are not limited to epilepsy, chronic pain, ALS, mania, cancer, anxiety, diabetes, tremor,
5 parkinsonism, migraine, ataxia, mood, sleep interference, multiple sclerosis and inflammation).

In a preferred aspect of the invention, a method is provided for protecting mammalian cells from abnormal levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D in cells, comprising introducing into mammalian cells an expression vector comprising a
10 DNA sequence substantially similar to the DNA sequence shown in SEQ ID NOS 3 or 4, that is operatively linked to a DNA sequence that promotes the expression of the DNA sequence and incubating the cells under conditions wherein the DNA sequence of SEQ ID NOS 3 or 4 will be expressed at high levels in the mammalian cells. Suitable expression vectors are as described above. In a
15 preferred embodiment, the coding region of the human $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene is subcloned into an expression vector under the transcriptional control of the cytomegalovirus (CMV) promoter to allow for constitutive $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene expression.

In another preferred aspect of the present invention, a method is provided
20 for treating or preventing abnormal levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D in VSCCs, comprising introducing into mammalian tumor cells an expression vector comprising a DNA that is antisense to a sequence substantially similar to the DNA sequence shown in SEQ ID NOS 3 or 4 that is operatively linked to a DNA sequence that promotes the expression of the antisense DNA sequence. The cells
25 are then grown under conditions wherein the antisense DNA sequence of SEQ ID NOS 3 or 4 will be expressed at high levels in the mammalian cells.

In a most preferred embodiment, the DNA sequence consists essentially of SEQ ID NOS 3 or 4. In a further preferred embodiment, the expression vector comprises an adenoviral vector wherein $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D cDNA is operatively
30 linked in an antisense orientation to a cytomegalovirus (CMV) promoter to allow for constitutive expression of the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D antisense cDNA in a host

-27-

cell. In a preferred embodiment, the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D adenoviral expression vector is introduced into cells by injection into a mammal.

Another aspect of the invention is to provide assays useful for determining if a compound of interest can bind to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins. This binding may interfere with, or mimic, the binding of ligands to the VSCCs, or this binding may affect the function of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D in modulating calcium flux. The assay comprises the steps of measuring the binding of a compound of interest to an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. Either the $\alpha 2\delta$ -C and/or the $\alpha 2\delta$ -D protein or the compound of interest to be assayed may be labeled with a detectable label, e.g., a radioactive or fluorescent label, so as to provide for the detection of complex formation between the compound of interest and the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein. In another embodiment of the subject assays, the assays involve measuring the interference, i.e., competitive binding, of a compound of interest with the binding interaction between an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein and a ligand already known to bind to $\alpha 2\delta$ -A protein. For example, the effect of increasing quantities of a compound of interest on the formation of complexes between radioactivity labeled ligand and an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein may be measured by quantifying the formation of labeled ligand- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein complex formation. In another embodiment of the subject assays, the assays involve measuring the alteration, i.e., non-competitive inhibition, of a compound of interest with the activity of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein (compounds which bind to a different region of $\alpha 2\delta$ and inhibit $\alpha 2\delta$ activity, but don't prevent binding of ligands such as gabapentin).

Polyclonal antibodies to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins generally are raised in animals by multiple subcutaneous (se) or intraperitoneal (ip) injections of an $\alpha 2\delta$ protein and an adjuvant. It may be useful to conjugate the $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein or a fragment containing the target amino acid sequence to a protein that is immunogenic in the species to be immunized, e.g. keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues),

-28-

N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl_2 , or $\text{R}_1\text{-N}=\text{C}=\text{NR}$, where R and R_1 are different alkyl groups.

Animals are immunized against the immunogenic conjugates or derivatives by combining 1 mg or 1 μg of conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for anti- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein antibody titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein, but also may be conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response.

Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies. For example, the anti- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein monoclonal antibodies of the invention may be made using the hybridoma method first described by Kohler & Milstein, *Nature* 256:495 (1975), or may be made by recombinant DNA methods [Cabilly, et al, U.S. Pat. No. 4,816,567].

Antibodies can also be generated using phage display. In this approach libraries of peptides of random sequence are generated in antibody genes cloned into phage. These phage libraries are screened for antibodies by screening against the immobilized protein. (Hoogenboom-HR, *Trends-Biotechnol.* 1997 Feb; 15(2): 62-70)

In the hybridoma method, a mouse or other appropriate host animal, such a hamster is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*.

-29-

Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Coding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (academic Press, 1986)].

5 The anti- $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein specific antibodies of the invention have a number of uses. The antibodies may be used to purify $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins from either recombinant or non-recombinant cells. The subject antibodies may be used to detect and/or quantify the presence of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins in tissue samples, e.g., from blood, skin, and the like. Quantitation of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D proteins may be used diagnostically for those
10 diseases and physiological or genetic conditions that have been correlated with particular levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein expression levels.

In a further aspect, the present invention provides a diagnostic assay for detecting cells containing $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D deletions, comprising isolating total genomic DNA from the cell and subjecting the genomic DNA to PCR
15 amplification using primers derived from the DNA sequence of SEQ ID NOS 3 or 4.

This aspect of the invention enables the detection of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D deletions in any type of cell, and can be used in genetic testing or as a laboratory tool. The PCR primers can be chosen in any manner that allows the amplification
20 of an $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene fragment large enough to be detected by gel electrophoresis. Detection can be by any method, including, but not limited to ethidium bromide staining of agarose or polyacrylamide gels, autoradiographic detection of radio-labeled $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D gene fragments, Southern blot hybridization, and DNA sequence analysis. In a preferred embodiment, detection
25 is accomplished by polyacrylamide gel electrophoresis, followed by DNA sequence analysis to verify the identity of the deletions. PCR conditions are routinely determined based on the length and base-content of the primers selected according to techniques well known in the art (Sambrook et al., 1989).

An additional aspect of the present invention provides a diagnostic assay
30 for detecting cells containing $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D deletions, comprising isolating total cell RNA and subjecting the RNA to reverse transcription-PCR amplification using primers derived from the DNA sequence of SEQ ID NOS 3 or 4. This

-30-

aspect of the invention enables the detection of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D deletions in any type of cell, and can be used in genetic testing or as a laboratory tool.

Reverse transcription is routinely accomplished via standards techniques (Ausubel et al., in Current Protocols in Molecular Biology, ed. John Wiley and Sons, Inc., 1994) and PCR is accomplished as described above.

The present invention may be better understood with reference to the accompanying examples that are intended for purposes of illustration only and should not be construed to limit the scope of the invention, as defined by the claims appended hereto.

Examples

Example 1

The sequence for human $\alpha 2\delta$ -A, c-DNA Accession No. M76559.1, was used to perform standard BLASTP searches against the Genbank non-redundant protein database and TBLASTN searches against the expressed sequence tag database (dbEST). Four full-length RNA sequences were identified (c-DNA Accession Nos. AF040709.1, AF042792.1, AF042793.1, and AB011130.1) which were highly homologous to $\alpha 2\delta$ -A. The DNA sequence of $\alpha 2\delta$ -B is provided by SEQ ID NO 1 and the amino acid sequence of $\alpha 2\delta$ -B is provided by SEQ ID NO 2. Using standard alignment tools, these four sequences were found to represent 4 different variants of the same gene. This gene was named $\alpha 2\delta$ -B. Further searches of the sequence databases, and analysis of proprietary clustered sequences generated using Compugen software, led to the identification of additional sequences related to $\alpha 2\delta$ -B. This includes human ESTs (Accession Nos. T80372.1, AA360556.1, AI563965.1, N53512.1, a mouse EST (Accession No. AA000341.1), and a sequence from *C.elegans* (Accession No. CAA90091.1). Since the initial identification of $\alpha 2\delta$ -B, additional related sequences have been deposited into the Genbank database. These correspond to Accession Nos. (human: AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1,

-31-

AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1,
AA435601.1, AI094263.1; mouse: AA008996.1; rat: AI105056.1,
AI502878.1).

A2 δ -B is 53 % identical and 69% similar at the amino acid level to α 2 δ -A.
5 The α 2 δ -B mRNA is 5482 bp long, and codes for a protein of 1145 amino acids.
The three splice-variants of α 2 δ -B which were identified differ only in the 5'
untranslated region, and do not alter the amino acid sequence. A2 δ -B aligns to
genomic sequence from a previously published cosmid contig on human
chromosome 3p21.3. This DNA contig covers more than 600kb of sequence. The
10 Accession Nos. for these genomic sequences are Z84493.1, Z84494.1, Z75743.1,
Z75742.1, and Z84492.1. Analysis of the DNA sequences flanking α 2 δ -B led to
the identification of genes flanking α 2 δ -B on human chromosome 3p21.3 which
had been mapped in both human and mouse. These flanking genes include CIS,
Hyal1, GNAI-2, and GNAT-1. In mouse, all of the flanking genes were localized
15 to mouse chromosome 9, 60cM. Analysis of mapping data stored in the Mouse
Genome Database, by Jackson Laboratory, led to the identification of three mouse
neurological phenotypes that had been genetically mapped to the same mouse
chromosome 9, 60cM region. These phenotypes include epilepsy1, ducky and
tippy. Epilepsy1 and ducky both have spike-wave activity consistent with
20 epilepsy. This tentatively maps α 2 δ -B to the chromosome 9, 60cM region in
mouse, and identifies α 2 δ -B as a candidate gene for the mouse mutants ducky,
tippy, and Ell (for overview of mapping data see Figure 1).

Northern and RT-PCR analysis of RNA expression levels of human α 2 δ -B
were performed to analyze the expression pattern of α 2 δ -B. For Northern
25 analysis, multiple tissue Northern blots and brain blots were obtained from
Clontech. Non-isotopic DNA probes for α 2 δ -B were generated by PCR using
SEQ ID NOS 7-8 and SEQ ID NO 1 as a template. Hybridization and washing
conditions were in accordance with the manufacturer's instructions (Boehringer
Mannheim). A2 δ -B was found to have highest expression in lung, and was also
30 detected in brain, heart, skeletal muscle, and at lower levels in all tissues tested
(Figure 2). For the Northern blot surveying different areas of human brain, α 2 δ -B
had the highest level of expression in the cerebral cortex, but was detected in all

-32-

areas of the human brain (Figure 2). RT-PCR expression analysis of human $\alpha 2\delta$ -B was also performed. RT-PCR analysis, using a cDNA tissue panel obtained from Clontech and SEQ ID NOS 7-8 for PCR-based gene amplification (cycles: 1X at 94 C 1', 35X at 94 C 0.5', 55 C 1', 72 C 2'; 1X at 72 C 10'), produced an expression pattern for $\alpha 2\delta$ -B consistent with results from Northern analysis. Overall, the expression pattern of $\alpha 2\delta$ -B is consistent with a proposed role of $\alpha 2\delta$ -B in epilepsy.

In order to determine if $\alpha 2\delta$ -B has functional properties comparable to $\alpha 2\delta$ -A, the ability of $\alpha 2\delta$ -B to bind to amino acids and gabapentin was measured. For this analysis, COS-7 cells were transiently transfected with the full-length porcine $\alpha 2\delta$ -A, and human $\alpha 2\delta$ -B genes each in the vector pcDNA3 (Invitrogen)(pcDNA3.1 for $\alpha 2\delta$ -B) by the lipofectamine mediated transfection method. The cells were transfected and membranes harvested by the generic methods outlined below. The K_D for binding of [3 H] gabapentin to $\alpha 2\delta$ -B, as compared to $\alpha 2\delta$ -A, can be found in Table 1. Additional binding studies were performed using techniques similar to those outlined below. Alterations to the protocol are listed below under the subheading "Alternative Method for Measuring [3 H] Gabapentin binding". The data for these binding studies are in figure 3. Overall, the binding and Western data demonstrated that the porcine $\alpha 2\delta$ -A and human $\alpha 2\delta$ -B full-length gene-products expressed transiently in the COS-7 system bind [3 H]gabapentin with high affinity.

Table 1: Saturation binding data for $\alpha 2\delta$ -B

Porcine $\alpha 2\delta$ -A (n=2)	Human $\alpha 2\delta$ -B (n=2)
K_D , 23.1 nM	K_D , 32.6 nM
K_D , 21.2 nM	K_D , 87.2 nM
<i>Mean = 22.2 nM</i>	<i>Mean = 59.9 nM</i>

-33-

Transient Transfection method (150mm plate)

- 5 1: Seed 3.9×10^6 COS-7 cells/150mm plate in 42ml DMEM + 10% FBS +
5u/ml Penicillin / 5µg/ml Streptomycin on 150mm plate. Grow O/N.
- 2: Setup
- Tube A – 30ug DNA in 300ul TE + 1.8ml Optimem (5u/ml Penicillin /
5µg/ml Streptomycin)
- 10 Tube B – 150ul Lipofectamine + 1.95ml Optimem (5u/ml Penicillin /
5µg/ml Streptomycin)
- 3: At time=0 mix tubes A and B and leave at RT for 45 minutes.
- 4: Wash cells with 30ml Optimem (5u/ml Penicillin / 5µg/ml
Streptomycin) twice then add 16.8ml Optimem (5u/ml Penicillin / 5µg/ml
Streptomycin) to the plates. At t=45 minutes add A/B mix to plates.
- 15 5: At t=6 hours add 21ml of Optimem (5u/ml Penicillin / 5µg/ml
Streptomycin).
- 6: At t=24 hours replace medium with 42ml Optimem (5u/ml Penicillin /
5µg/ml Streptomycin)
- 7: At t=48 hours rinse the cells twice with 20ml of PBS then harvest.

20

Membrane preparation (perform at 4°C)

- 1 Harvest cells into a 2ml eppendorf in 1.5ml 1mM EDTA/1mM
EGTA/0.1mM PMSF (added immediately prior to use from a 1000x
stock)/20% Glycerol/10mM HEPES pH7.4 @ 4°C using a cell scraper.
- 25 2 Mix cells end-over-end for 30 minutes at 4°C then centrifuge at
20,000 x g for 5 minutes.
- 3 Resuspend pellet in 1.5ml 1mM EDTA/1mM EGTA/20%
Glycerol/10mM HEPES pH7.4 @ 4°C then immediately re-centrifuge at
20,000 x g for 5 minutes.

-34-

4 Resuspend pellet to ~1mg/ml (protein concentration as determined by the Bradford protein assay) in 1mM EDTA/1mM EGTA/20% Glycerol/10mM HEPES pH7.4 @ 4°C

5 For total [³H] binding, cells were sonicated for 30-40 seconds, centrifuged for 10' at 750-1000Xg, and the supernatant was centrifuged for 30' at 50,000Xg. The resulting pellet was resuspended in 5mM

[³H]Gabapentin saturation binding assay methodology and data analysis

10 Assays were carried out at 21°C in a final volume of 250µl in 96-well deep-well plates. Duplicate wells were set up for both 'total' and 'non-specific' binding. Specific binding was defined as that remaining after subtraction of the 'non-specific binding' values from the 'total' binding values. Assay components were added in the following order (all reagents were diluted in 10mM HEPES (pH 7.4 at 21°C)):

15 Total binding 200µl 10mM HEPES pH 7.4

Non-specific binding 175µl 10mM HEPES pH 7.4 and 25µl 100µM
(S+)-3-isobutyl GABA

25µl Appropriate COS membrane sample

20 25µl [³H]gabapentin

The reaction was incubated at 21°C for 45 minutes then filtered through GF/B filters soaked in 50 mM Tris-Cl pH 7.4 @4°C (wash buffer), filters were washed three times with wash buffer.

25

The filters were then counted in a scintillation counter.

Saturation experiments were performed with 12 duplicate data points ('Total' and 'Non-Specific' binding determined in duplicate for each concentration of [³H]gabapentin tested) and a [³H]gabapentin concentration range from ~1 to 400nM. Data was analyzed using KEL-RADLIG for Windows.

30

Alternative Method for Measuring [³H] Gabapentin binding

The method described above was followed with the following exceptions:

5 1) **COS7 transfection:** 20ug of $\alpha 2\delta$ -A or $\alpha 2\delta$ -B plasmid DNA were incubated with 30ul of lipofectamine. The mixture was overlaid onto the cells in 1.5ml of serum-free medium and incubated for 5 hours. Then FBS was added to the dishes to bring the final concentration to 10%. The medium was changed the next morning. Forty-eight hours after transfection the cells were harvested for membrane preparation.

10 2) **Membrane preparation:** Cells were washed twice with cold PBS and then scraped off the tissue culture plates in cold 5mM of Tris/5mM EDTA (pH7.4) containing PMSF (0.1mM), leupeptin (0.02mM), and pepstatin (0.02mM). The cells were incubated on ice for 30 minutes and then sonicated for 30-40 seconds. The homogenate was
15 centrifuged for 10 minutes at 750-1000xg, and then the supernatant was centrifuged for 30 minutes at 50,000xg. The resulting pellet was resuspended in the same buffer as described above.

 3) **Binding Assays:** The radioligand binding assay was done using 0.05 mg of membrane protein incubated in the presence of 20 nM of
20 [³H] gabapentin. The membranes were incubated in 10 mM Hepes (pH 7.4) for 40-50 minutes at room temperature, and then filtered onto pre-wetted GF/C membranes and quickly washed five times with 3ml of ice cold 50mM tris buffer pH7.4. The filters were dried and counted in a
25 liquid scintillation counter. To determine background binding, 10 uM of isobutyl GABA was used and the resulting counts subtracted from the total counts of each sample.

Detection of $\alpha 2\delta$ -A and $\alpha 2\delta$ -B expression with anti- α_2 polyclonal antibodies

30 Using affinity purified anti- α_2 polyclonal antibodies (antigen derived from porcine $\alpha_2\delta$ -A; See Brown and Gee (1998) *JBC* 273 25458-25465 for pAb

-36-

generation details) the expression of the porcine $\alpha_2\delta$ -A and human $\alpha_2\delta$ -B proteins (over and above control levels - COS cells transfected with the parent pcDNA3 vector) was confirmed. N.B. Cross reaction of the pAb's with $\alpha_2\delta$ -B was not unexpected given the ~50% amino acid sequence identity. Furthermore, and with reference to Example 2, expression of $\alpha_2\delta$ -C was not detected using this antibody (sequence identity with $\alpha_2\delta$ -A ~30%).

Example 2

The sequence for human $\alpha_2\delta$ -A, Accession No. M76559.1, was used to perform standard BLASTP searches against the Genbank non-redundant protein database and TBLASTN searches against the expressed sequence tag database (dbEST). EST sequences were identified (Accession Nos. AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1, AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1) corresponding to a new gene, with similarity to $\alpha_2\delta$ -A, named $\alpha_2\delta$ -C. Additional searches of the sequence databases led to the identification of other sequences related to $\alpha_2\delta$ -C. This includes a mouse EST (Accession No. AU022914.1, AI843362.1), and an STS (Accession No. G36524.1) which maps to human chromosome 3p21.1. Since the initial identification of $\alpha_2\delta$ -B, additional related sequences have been deposited into the Genbank database. These correspond to Accession Nos. (human ESTs: AA459804.1, AI696320.1, AI051759.1, AI696214.1; human genomic sequence: AC010180.1; mouse EST: AA445859.1, mouse RNA: AJ010949.1).

In order to clone a full-length $\alpha_2\delta$ -C, a PCR-based cDNA library screen was carried out by Origene using primers (SEQ ID NOS 9-10) based on sequence derived from EST clone accession number AA190607.1 which were designed to amplify a 273 bp fragment. A positive clone was identified in a kidney library. After sequencing, this clone was identified as a novel 3' splice variant (SEQ ID NO 43). The protein sequence, which can be derived from SEQ ID NO 43, of this novel splice variant is a truncated, potentially secreted soluble form of $\alpha_2\delta$ -C. PCR was performed, using primers (SEQ ID NOS 9 and 11) and a human adult

-37-

brain library from LTI as a template, and the resulting fragment of 248 bp was cloned in pBS and sequence verified. A SacI-NcoI fragment from the kidney clone, a NcoI-KpnI fragment from the PCR center clone, and a KpnI-NotI fragment from a clone obtained from the IMAGE consortium (corresponding to Accession No. R43629.1) were ligated together, using methods standard to the art, to create a full-length clone. Each individual clone, and the full-length clone (SEQ ID NO 3), were sequence verified. A number of other EST clones from the IMAGE consortium were also obtained and sequenced. One of these clones (corresponding to Accession No. AI051759.1) contained a two novel splice-variants which result in a truncated, potentially soluble $\alpha_2\delta$ -C (SEQ ID NO 44).

Full-length $\alpha_2\delta$ -C is 28 % identical and 48% similar at the amino acid level to $\alpha_2\delta$ -A. The $\alpha_2\delta$ -C mRNA sequence (SEQ ID NO 3) is 3770 bp long, and codes for a protein of 1085 amino acids (SEQ ID NO 5). In addition, three splice variants of $\alpha_2\delta$ -C were identified. Two of the variants contain deletions of internal exons. The third variant contains a novel 3' end. Two of these splice-variants produce a truncated protein which is devoid of the membrane anchoring delta subunit. These variants may represent a secreted alpha2 protein which could have additional functions beyond regulation of voltage-sensitive calcium channels.

In order to identify sequences for $\alpha_2\delta$ -C from other species, human and mouse specific primers (SEQ ID NOS 9-10 and 12-13, respectively) were used to amplify $\alpha_2\delta$ -C RT-PCR products. RNA from human brain was purchased from Invitrogen, Carlsbad, CA (catalog #D6030-15). RNA from rat and mouse brain was isolated using standard in-house protocols. First-strand cDNA synthesis was completed using Superscript Choice System (LTI, Bethesda, MD, catalog #18090-019). Ethanol precipitated cDNA was added to PCR mix containing 1X PCR buffer, 0.2mM dNTP, 10pmol/well forward primer, 10pmol/well reverse primer, and 0.5 units Platinum TAQ High Fidelity (LTI, Bethesda, MD). Products were amplified at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 1 minute, 58° C for 1 min, 68° C for 2 minutes, and final extension at 72 °C for 10 minutes. PCR products were assayed on 1% agarose (TAE) gels at 100 volts for 45 minutes. Gels were visualized under UV and photographed. Products

-38-

were purified using Millipore Ultrafree-MC PCR purification filter units (catalog # UFC3LTKOO) prior to DNA sequence analyses. Using this approach, three sets of primers (SEQ ID NO 36, 37; SEQ ID NO 12, 13, SEQ ID NO 38, 39) where used for PCR amplification of rat $\alpha 2\delta$ -C. Three partial rat sequences for $\alpha 2\delta$ -C were identified (SEQ ID NOS 40, SEQ ID NO 14, SEQ ID NO 41).

RT-PCR analysis of RNA expression levels were performed to analyze the expression pattern of $\alpha 2\delta$ -C. cDNA Expression Panels were purchased from OriGene Technologies, Inc. (Rockville, Maryland). Human (catalog # HSC-101) and Mouse (catalog # MSCB-101) cDNAs from 24 tissue sources were pre-arrayed in a 96-well PCR format. PCR mix containing 1X PCR buffer, 0.2mM dNTP, 10pmol/well forward primer, 10pmol/well reverse primer, and 0.5 units Platinum TAQ (LTI, Bethesda, MD) was added to each well. Products were amplified at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 1 minute, 58° C for 1 min, 68° C for 2 minutes, and final extension at 72 °C for 10 minutes. PCR products were assayed on 1% agarose (TAE) gels at 100 volts for 45 minutes. Gels were visualized under UV and photographed. The primers used for this amplification from the human template correspond to SEQ ID NOS 9-10, and from the mouse template correspond to SEQ ID NOS 12-13. By RT-PCR, $\alpha 2\delta$ -C was found to be expressed in a wide variety of tissues (Table 2). The highest levels of $\alpha 2\delta$ -C were detected in human brain, and also in human testis and kidney. In addition to RT-PCR, the cDNA sequence for this gene has been detected in a human, adult brain library and also libraries from: infant brain, hNT neural cell line, testis, total fetus, alveolar rhabdomyosarcoma, adenocarcinoma, and a pooled germ cell library.

Northern blot analysis was performed using $\alpha 2\delta$ -C as a probe. Human total RNA was obtained from Invitrogen (Carlsbad, CA) (brain. total RNA(Cat #D6030-01), kidney total RNA (Cat #D6070-01), testis total RNA(Cat #D6121-01), liver total RNA(Cat # D6080-015)) or Ambion Inc(Austin, TX)(placenta total RNA Cat#7950, heart total RNA Cat #7966), lung total RNA(Cat #7968)) RNA was electrophoresed in formaldehyde agarose gels then transferred to charged nylon membranes(Ambion Inc. (Austin TX) Cat #10104. The EST clone (SEQ ID NO 47) was digested with BamHI and used as template in an RNA synthesis

-39-

reaction that yielded ^{32}P labeled probe. The nylon membranes containing the RNA were prehybridized for 2 hours in ExpressHyb hybridization solution (Clontech Inc. (Palo Alto, CA)(Cat # 8015-1). After the prehybridization 4×10^6 cpm of RNA probe labeled with ^{32}P were added to the solution and the hybridization was performed in the same solution for 2 hours. After hybridization the nylon filter was washed for 1 hour with 4 changes of $2\times$ SSC, 0.5% SDS at room temperature. The nylon filter was transferred to a solution of $0.2\times$ SSC, 0.5% SDS at 68°C and washed with 4 changes of solution. The nylon filters were then exposed to phosphorimager screens Molecular Dynamics(Sunnyvale, CA) and read on a Storm phosphorimager. Molecular Dynamics(Sunnyvale, CA). Results from Northern analysis (Figure 4) indicate that $\alpha_2\delta$ -C has highest levels of expression in human brain, kidney, and testis.

Since $\alpha_2\delta$ -C has sequence homology to $\alpha_2\delta$ -A, and $\alpha_2\delta$ -A functions as a subunit of VSCCs, experiments were undertaken to determine if $\alpha_2\delta$ -C can replace $\alpha_2\delta$ -A and produce functional VSCCs. *Xenopus* oocytes were isolated using standard techniques and injected with cRNA for α_{1B} , β_{1C} and $\alpha_2\delta$ -C subunits of voltage-gated Ca^{2+} channels. Four days to 1 week following injection of cRNA, Ca^{2+} channel currents were measured using two-electrode voltage clamp with 5 mM Ba^{2+} as the charge carrier. Test pulses to +10 mV from a holding membrane potential of -80 mV were applied to evoke Ca^{2+} channel currents. Peak inward currents evoked during the test pulse were measured. The amplitude of inward currents is proportional to the expression level of voltage-gated Ca^{2+} channels.

Expression of α_{1B} , β_{1C} without $\alpha_2\delta$ subunits produced currents with an average amplitude of 105 ± 13 nA ($n=20$). Co-injection of $\alpha_2\delta_c$ with α_{1B} and β_{1C} subunits produced a significant increase in current amplitude to 213 ± 12 nA ($n=20$, $p < 0.01$ compared to no $\alpha_2\delta$ subunits). These data suggest that $\alpha_2\delta_c$ has an effect on Ca^{2+} channels similar to $\alpha_2\delta_A$, enhancing the level of channel expression. However, $\alpha_2\delta_c$ did not produce as large of an effect on channel expression as $\alpha_2\delta_A$, producing a 2-fold increase in current compared to a 20-fold increase observed with the co-injection of $\alpha_2\delta_A$. Overall, these initial functional

-40-

studies indicate that $\alpha_2\delta$ -C can replace $\alpha_2\delta$ -A in voltage-sensitive calcium channels after co-injection into *Xenopus* oocytes with the $\alpha 1$ and beta subunits.

Table 2: RT-PCR EXPRESSION PROFILE FOR ALPHA2-DELTA C

5	<i>Tissue</i>	<i>Human $\alpha 2\delta$-C</i>	<i>Mouse $\alpha 2\delta$-C</i>
	Brain	+++	+
	Heart	++++	-
	Kidney	++	++
10	Liver	-	-
	Colon	+	not assayed
	Lung	+	++
	Small Intestine	++	+
	Muscle	++++	++
15	Stomach	++	-
	Testis	+++	++
	Placenta	++	not assayed
	Salivary Gland	++	not assayed
	Thyroid Gland	++	not assayed
20	Adrenal Gland	++	-
	Pancreas	++	not assayed
	Ovary	++	-
	Uterus	++	-
	Prostrate	++	++
25	Skin	++	-
	PBL	-	not assayed
	Bone Marrow	-	not assayed
	Fetal Brain	++	not assayed
30	Fetal Liver	++	not assayed

Example 3

The sequence for human $\alpha 2\delta$ -A, Accession No. M76559.1, was used to perform BLASTP searches against the Genbank non-redundant protein database

-41-

and TBLASTN searches against the expressed sequence tag database (dbEST). EST sequences were identified (Accession No. T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1, AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1, H86016.1) corresponding to a new gene, with similarity to $\alpha 2\delta$ -A, named $\alpha 2\delta$ -D. Additional searches of the sequence databases led to the identification of other sequences related to $\alpha 2\delta$ -D. This includes genomic sequence derived from human chromosome 12p13.3 (Accession No. AC005342.1, AC005343.1). Since the initial identification of $\alpha 2\delta$ -D, additional related sequences have been deposited into the Genbank database. These sequences correspond to Accession Nos. (human ESTs: T96900.1, AI457823.1, AI377638.1, and AI433691.1).

To isolate a full-length $\alpha 2\delta$ -D clone, a PCR-based cDNA library screen was carried out by Origene using primers (SEQ ID NOS 18-19) based on sequence derived from EST clone Accession No. AA001473.1 which were designed to amplify a 372 bp fragment. A positive clone was identified in a placental library, and was confirmed using a nested internal primer (SEQ ID NO 20). This clone was fully sequenced. The sequence extended 350 bp 5' of the sequence obtained from the EST sequences, but did not include the 5' end.

To obtain the 5' end, two approaches were undertaken. One approach utilized 5' RACE (Rapid Amplification of cDNA Ends). For 5' RACE, placenta poly A+ RNA from Clontech was used to construct a RACE-ready cDNA library using a Marathon cDNA Amplification kit purchased from Clontech. The 5'-end sequence of $\alpha 2\delta$ -D was obtained by 5' RACE PCR using first set of primers: Marathon cDNA adapter primer 1 (SEQ ID NO 45) and gene specific primer I (SEQ ID NO 21). The PCR product was re-amplified using a set of nested primers: adapter primer 2 (SEQ ID NO 46) and gene specific primer II (SEQ ID NO 22). A resulting 1 kb PCR product was cloned into a TA vector (Invitrogen) and sequenced. Sequence analysis revealed that it contains the 5' sequence of $\alpha 2\delta$ -D.

A second method undertaken to identify the 5' end of $\alpha 2\delta$ -D was a PCR-based library screen performed by Edge, using the 5' most sequence known for $\alpha 2\delta$ -D. Nine clones were PCR amplified by the methods indicated above, for

-42-

verification using primers with SEQ ID NOS 48 and 49. These nine positive clones were then sequenced for verification by standard methods. All nine clones were identical to each other, and all were short of the 5' end by approximately 500 bp. However, these clones contained novel splice-variants of $\alpha 2\delta$ -D, with
5 insertions of novel nucleotide sequences (SEQ ID NO 16).

The full-length sequence of $\alpha 2\delta$ -D is 28 % identical and 47% similar at the amino acid level to $\alpha 2\delta$ -A. The $\alpha 2\delta$ -D mRNA is 5,073 bp long (SEQ ID NO 4), and codes for a protein of 1120 amino acids (SEQ ID NO 6) . In addition, two splice variants of $\alpha 2\delta$ -D were identified. One of the variants contains a 72 bp
10 deletion of an internal exon (SEQ ID NO 15). The amino acid sequence of this variant can be found in SEQ ID NO 17. The second variant contains two novel insertions, one of 338 bp and one of 305 bp (SEQ ID NO 16). These insertions appear to result in a truncated protein (SEQ ID NO 42), comparable to the truncated protein sequence identified for $\alpha 2\delta$ -C in Example 2.

RT-PCR analysis of RNA expression levels of human $\alpha 2\delta$ -D were performed in order to analyze the tissue distribution of $\alpha 2\delta$ -D. cDNA Expression Panels were purchased from OriGene Technologies, Inc. (Rockville, Maryland). Human (catalog # HSC-101) and Mouse (catalog # MSCB-101) cDNAs from 24 tissue sources were pre-arrayed in a 96-well PCR format. PCR mix containing 1X
20 PCR buffer, 0.2mM dNTP, 10pmol/well forward primer, 10pmol/well reverse primer, and 0.5 units Platinum TAQ (LTI, Bethesda, MD) was added to each well. Products were amplified at 95 °C for 5 minutes, followed by 35 cycles of 95 °C for 1 minute, 58° C for 1 min, 68° C for 2 minutes, and final extension at 72 °C for 10 minutes. PCR products were assayed on 1% agarose (TAE) gels at 100
25 volts for 45 minutes. Gels were visualized under UV and photographed. In the case of the $\alpha 2\delta$ -D human panels two separate sets of primers were used to distinguish splice variants and wild type species (SEQ ID NOS 18 & 20, SEQ ID NOS 23 & 19, respectively).

Analysis of the results from RT-PCR of $\alpha 2\delta$ -D (see Table 3) indicate that
30 $\alpha 2\delta$ -D is expressed in a wide variety of tissues, with highest levels in placenta, adrenal gland and pancreas, but also detected in all tissues other than colon. Of note, $\alpha 2\delta$ -D was detected in human brain, consistent with a potential role in

-43-

neurological disease. In addition, based on the tissue distribution of EST sequences, the cDNA sequence for $\alpha_2\delta$ -D has been detected in human libraries from: adult brain, retina, fetal liver/spleen, fetal heart, pineal gland, and testis.

5 Table 3. RT-PCR EXPRESSION PROFILE FOR ALPHA2-DELTA D

	Tissue	Human $\alpha_2\delta$ -D **	Human $\alpha_2\delta$ -D
	Brain	+++	+++
	Heart	+++	-
10	Kidney	+++*	-
	Liver	++	-
	Colon	-	-
	Lung	++	-
	Small Intestine	++	-
15	Muscle	++	-
	Stomach	++	-
	Testis	+++	-
	Placenta	++++*	-
	Salivary Gland	++	++++
20	Thyroid Gland	+++	++++
	Adrenal Gland	++++	+++
	Pancreas	++++*	++
	Ovary	++*	++
	Uterus	++	++
25	Prostrate	++*	+
	Skin	+	-

-44-

PBL	+++	-
Bone Marrow	+++	-
Fetal Brain	+++	-
Fetal Liver	++	-

5

*2 products: wt and splice
variant

** Primers d2+dhD-2 detects
splice region

10 **Example 4. Knockout of $\alpha 2\delta$ -B**

In order to create a mouse knockout of $\alpha 2\delta$ -B, Genome Systems (Catalog: BAC 4922 Mouse ES 129Svj PCR based Library Screen) performed a PCR-based screen of a mouse BAC library using primers SEQ ID NOS 25-26, which were predicted to amplify an 650 bp cDNA or genomic fragment. One positive
15 BAC clone (Genome Systems DNA control number: BAC-22401) from this screen was received. The same primers were used to generate a human DNA probe. This probe was used on a Southern blot to identify a ~10kb HindIII mouse genomic fragment from the BAC, which was subcloned into the HindII site of plasmid vector pRS416 (Stratagene). Two separate subclones were sequenced by
20 standard techniques, using the T3 and T7 primers and SEQ ID NOS (25-32). Two 500 bp regions of sequence from the 5' and 3' ends of the 10kb genomic fragment (SEQ ID NOS 33 and 34, respectively), plus a 1.8kb sequence contig (SEQ ID NO 35) were identified. This genomic sequence can be used to identify the intron/exon structure of a portion of mouse $\alpha 2\delta$ -B gene, and may contain
25 regulatory elements important for $\alpha 2\delta$ -B gene expression.

Example 5. Identification of amino acids encoded by $\alpha 2\delta$ gene

The amino acid sequences of $\alpha 2\delta$ -C and $\alpha 2\delta$ -D, indicated in SEQ ID NOS 5 and 6, were determined by translating the nucleotide sequences described in
30 SEQ ID NOS 3 and 4, and aligning the amino acid sequences of $\alpha 2\delta$ -A, $\alpha 2\delta$ -B, $\alpha 2\delta$ -C, and $\alpha 2\delta$ -D. The correct open reading frame for each amino acid sequence was determined based on homology of the amino acid sequences to other $\alpha 2\delta$ -A

-45-

homologs. At the amino acid level, $\alpha 2\delta$ -C is 28% identical and 48% similar to $\alpha 2\delta$ -A and is 28% identical and 47% similar to $\alpha 2\delta$ -B, and $\alpha 2\delta$ -D is 28% identical and 47% similar to $\alpha 2\delta$ -A and is 28% identical and 46% similar to $\alpha 2\delta$ -B. Although $\alpha 2\delta$ -C and $\alpha 2\delta$ -D are related to $\alpha 2\delta$ -A, they are distinctly new and different genes.

Example 6. Proposed method of detecting the $\alpha 2\delta$ -C and $\alpha 2\delta$ -D proteins by using $\alpha 2\delta$ -C and $\alpha 2\delta$ -D antibody

Antibodies could be developed which specifically detect epitopes unique to $\alpha 2\delta$ -C and $\alpha 2\delta$ -D, or which detect all $\alpha 2\delta$ proteins. These antibodies could be developed by either synthesizing a peptide which is identical to $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, or by bacterially-expressing a fusion protein containing either $\alpha 2\delta$ -C or $\alpha 2\delta$ -D, and then injecting these peptides into a research animal in order to stimulate an immunogenic response. Antibodies generated in such a manner could be used to detect levels of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D protein in cells. This could be done by immunocytochemistry, where whole cells are fixed and then the antibody is used on the whole cells to detect expression of $\alpha 2\delta$ -C or $\alpha 2\delta$ -D, and to detect the subcellular localization of $\alpha 2\delta$ -C or $\alpha 2\delta$ -D. Or, cells may be lysed and protein extracts generated and analyzed for $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D expression.

Example 7. Isolation of RNA for cDNA Library

In order to isolate $\alpha 2\delta$ -C or $\alpha 2\delta$ -D from cells, RNA could be isolated by lysing cells from any tissue of interest using standard methods known in the field. After isolation, RNA is reverse-transcribed into cDNA using the enzyme reverse transcriptase and a poly(T) primer or a mix of random primers. A mix of cDNA is produced, representing a large number of the genes which are expressed in the beginning cell population at a particular point in time. Once the cDNA pool has been created, it can be restricted and then ligated into a cloning vector using methods standard in the field. This results in a cDNA library.

-46-

Example 8. cDNA Cloning Procedure

A2 δ -C or α 2 δ -D could be cloned from a cDNA library, created as above, by using primers specific for α 2 δ -C or α 2 δ -D nucleotide sequences in a polymerase chain reaction, with the cDNA used as a template. Alternatively,
5 α 2 δ -C or α 2 δ -D sequences could be used as a probe in order to screen the cDNA library by hybridization. Using either technique, single clones are ultimately isolated from the library and sequenced using standard techniques. By sequencing multiple clones from a library, one could look for the existence of alternatively-spliced variants of α 2 δ -C or α 2 δ -D, or for the existence of single nucleotide
10 polymorphisms, or for mutations/alterations in α 2 δ -C or α 2 δ -D.

Example 9. Screening cDNA Library with Antibody

A cDNA library could also be screened by using an antibody to α 2 δ -C or α 2 δ -D. The cDNA library is cloned into a vector which allows induction of protein
15 expression of the cloned inserts. The complete cDNA library is induced to express a protein representing the cloned insert, then single clones which contain an insert that codes for α 2 δ -C or α 2 δ -D are identified if they hybridize to an antibody generated against α 2 δ -C or α 2 δ -D. Positive clones are isolated, and then sequenced using standard methods.

20

It is to be understood that the invention is not to be limited to the exact details of operation, or to the exact compounds, compositions, methods, procedures or embodiments shown and described, as obvious modifications and
25 equivalents will be apparent to one skilled in the art, and the invention is therefore to be limited only by the full scope of the appended claims.

-47-

We claim

1. An isolated and purified DNA sequence substantially similar to the DNA sequence shown in SEQ ID NOS 3 or 4.
2. An isolated and purified DNA sequence that hybridizes to the DNA sequence shown in SEQ ID NOS 3 or 4 under high stringency hybridization conditions.
3. An isolated and purified DNA sequence that consists essentially of the DNA sequence shown in SEQ ID NOS 3 or 4.
4. An isolated and purified DNA sequence that has at least a 70% identity to a polynucleotide encoding the polypeptide expressed by SEQ ID NOS 5 or 6.
5. An isolated and purified DNA sequence that is fully complementary to the DNA sequence shown in SEQ ID NOS 3 or 4.
6. A recombinant DNA molecule comprising the isolated and purified DNA sequence of Claim 3 or 4 subcloned into an extra-chromosomal vector.
7. A recombinant host cell comprising a host cell transfected with the recombinant DNA molecule of Claim 6.
8. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide is substantially similar to the amino acid sequence shown in SEQ ID NOS 5 or 6.
9. A substantially purified recombinant polypeptide of Claim 8, wherein the polypeptide has at least about 70% amino acid sequence similarity to the amino acid sequence shown in SEQ ID NOS 5 or 6.
10. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide consists essentially of the amino acid sequence shown in SEQ ID NOS 5 or 6.

-48-

11. An antibody that selectively binds polypeptides with an amino acid sequence substantially similar to the amino acid sequence of Claim 8.

12. A method of detecting $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein in cells, comprising contacting cells with the antibody of Claim 11 and incubating the cells in a manner that allows for detection of the $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein-antibody complex.

13. A diagnostic assay for detecting cells containing $\alpha 2\delta$ -C or $\alpha 2\delta$ -D mutations, comprising isolating total genomic DNA from the cell and subjecting the genomic DNA to PCR amplification using primers derived from the isolated and purified DNA sequence of Claim 1, 2, or 3 or by analyzing the genomic DNA directly by a hybridization method and determining whether the resulting PCR product contains a mutation.

14. A diagnostic assay for detecting cells containing $\alpha 2\delta$ -C or $\alpha 2\delta$ -D mutations, comprising isolating total cell RNA, subjecting the RNA to reverse transcription-PCR amplification using primers derived from the isolated and purified DNA sequence of Claim 1, 2, or 3 and determining whether the resulting PCR product contains a mutation.

15. A method for the amplification of a region of the DNA sequence of Claim 1, 2, or 3, the method comprising the step of: contacting a test sample suspected of containing the desired sequence of Claim 1, 2, or 3 or portion thereof with amplification reaction reagents.

16. A diagnostic kit for detecting the presence of at least one copy of the DNA sequence of Claim 1, 2, or 3 in a test sample, said kits containing a primer, a pair of primers or a probe, and optionally amplification reagents .

-49-

17. An assay for the detection or screening of therapeutic compounds that interfere with or mimic the interaction between the polypeptide of Claim 8, 9, or 10 and ligands that bind to the polypeptide of Claim 8, 9, or 10.
18. The assay of Claim 17, herein the assay comprises the steps of:
- 5 a) providing a polypeptide of Claim 8, 9, or 10;
- b) obtaining a candidate substance;
- c) bringing into contact said polypeptide with said candidate substance;
- and
- d) detecting the complexes formed between said polypeptide and said
- 10 candidate substance.
19. A method for protecting mammalian cells from abnormal calcium flux, comprising introducing into mammalian cells an expression vector comprising the isolated and purified DNA sequence of Claim 1, 2, or 3, which is operatively linked to a DNA sequence that promotes the high level expression of the isolated
- 15 and purified DNA sequence in mammalian cells.
20. A method for treating or preventing epilepsy, comprising introducing into a mammal an expression vector comprising the isolated and purified DNA sequence of Claim 1, 2, or 3, which is operatively linked to a DNA sequence that promotes the high level expression of the antisense strand of the isolated and
- 20 purified DNA sequence in mammalian cells.
21. A method for purifying $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein from cells, comprising:
- a) transfecting a host cell with a vector comprising the isolated and purified DNA sequence of Claim 1, 2, or 3 operatively linked to a promoter capable of directing gene expression in a host cell;

-50-

- b) inducing expression of the isolated and purified DNA sequence in the cells;
- c) lysing the cells;
- d) isolating $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein from the cells ; and
- 5 e) purifying $\alpha 2\delta$ -C or $\alpha 2\delta$ -D protein from the isolate.
22. An isolated and purified DNA sequence substantially similar to the DNA sequence shown in SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.
23. An isolated and purified DNA sequence that hybridizes to the DNA sequence shown in SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49 under high stringency hybridization conditions.
- 10 24. An isolated and purified DNA sequence that consists essentially of the DNA sequence shown in SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.
- 15 25. An isolated and purified DNA sequence that has at least a 70% identity to a polynucleotide encoding the polypeptide expressed by SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.
26. An isolated and purified DNA sequence that is fully complementary to the DNA sequence shown in SEQ ID NOS 11, 14-16, 21-24, 31-35, 40-41, 43-44, 47-48 or 49.
- 20 27. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide is substantially similar to the amino acid sequence shown in SEQ ID NOS 17 or 42.
28. A substantially purified recombinant polypeptide of Claim 26, wherein the

-51-

polypeptide has at least about 70% amino acid sequence similarity to the amino acid sequence shown in SEQ ID NOS 17 or 42.

29. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide consists essentially of the amino acid sequence shown in SEQ ID NOS 17 or 42.

30. An antibody that selectively binds polypeptides with an amino acid sequence substantially similar to the amino acid sequence of Claim 26.

31. A method of using polynucleotide sequences to treat diseases which may result from alterations of $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D genes or from alterations of cellular pathways involving $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, wherein the polynucleotide sequences are selected from the group consisting essentially of: M76559.1, AF040709.1, AF042792.1, AF042793.1, AB011130.1, T80372.1, AA360556.1, AI563965.1, N53512.1, AA000341.1, CAA90091.1, AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1, AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1, AA435601.1, AI094263.1, AA008996.1, AI105056.1, AI502878.1, Z84493.1, Z84494.1, Z75743.1, Z75742.1, Z84492.1, AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1, AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1, AU022914.1, AI843362.1, G36524.1, AA459804.1, AI696320.1, AI051759.1, AI696214.1, AC010180.1, AA445859.1, AJ010949.1, AA190607.1, AI051759.1, T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1, AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1, H86016.1, AC005342.1, AC005343.1, T96900.1, AI457823.1, AI377638.1, and AI433691.1, AA001473.1 and any of the polynucleotide sequences of SEQ ID NOS 1-16, 18-41, or 43-49.

32. The method of claim 31 wherein the disease is selected from the group consisting essentially of: seizure-related syndromes, migraine, ataxia, vestibular defects, chronic pain, mood, sleep interference, anxiety, ALS, multiple sclerosis,

-52-

mania, tremor, parkinsonism, substance abuse/addiction syndromes, mood, depression, and cancer.


33. A method of using polynucleotide sequences to test for presence of a disease, or susceptibility to a disease, due to alterations or deletions in $\alpha 2\delta$ -C and/or $\alpha 2\delta$ -D, wherein the polynucleotide sequences are selected from the group consisting essentially of: M76559.1, AF040709.1, AF042792.1, AF042793.1, AB011130.1, T80372.1, AA360556.1, AI563965.1, N53512.1, AA000341.1, CAA90091.1, AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1, AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1, AA435601.1, AI094263.1, AA008996.1, AI105056.1, AI502878.1, Z84493.1, Z84494.1, Z75743.1, Z75742.1, Z84492.1, AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1, AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1, AU022914.1, AI843362.1, G36524.1, AA459804.1, AI696320.1, AI051759.1, AI696214.1, AC010180.1, AA445859.1, AJ010949.1, AA190607.1, AI051759.1, T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1, AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1, H86016.1, AC005342.1, AC005343.1, T96900.1, AI457823.1, AI377638.1, and AI433691.1, AA001473.1 and any of the polynucleotide sequences of SEQ ID NOS 1-16, 18-41, or 43-49.

34. A method of using polynucleotide sequences to identify the binding potential of the polynucleotide sequences to gabapentin, wherein the polynucleotide sequences are selected from the group consisting essentially of: M76559.1, AF040709.1, AF042792.1, AF042793.1, AB011130.1, T80372.1, AA360556.1, AI563965.1, N53512.1, AA000341.1, CAA90091.1, AI027237.1, AI026646.1, AA994701.1, AA887514.1, AI275868.1, AI675521.1, AA906993.1, AA301068.1, AI884536.1, AI862563.1, AI191453.1, AI241832.1, AA534927.1, AA329137.1, AI586961.1, AA394008.1, AW007700.1, R38827.1, AA255807.1, H11152.1, R60736.1, T16903.1, AA435601.1, AI094263.1, AA008996.1,

-53-

- AI105056.1, AI502878.1, Z84493.1, Z84494.1, Z75743.1, Z75742.1, Z84492.1,
AA815447.1, AA190607.1, AI223142.1, AA188635.1, R43629.1, R20288.1,
AA459684.1, AA662058.1, Z44942.1, Z40693.1, AI051759.1, AU022914.1,
AI843362.1, G36524.1, AA459804.1, AI696320.1, AI051759.1, AI696214.1,
5 AC010180.1, AA445859.1, AJ010949.1, AA190607.1, AI051759.1,
T70594.1, T96901.1, AA766033.1, AI160471.1, AA719773.1, AI003601.1,
AA442451.1, AA521470.1, AA770076.1, AA001411.1, AA001473.1, W22650.1,
H86016.1, AC005342.1, AC005343.1, T96900.1, AI457823.1, AI377638.1, and
AI433691.1, AA001473.1 and any of the polynucleotide sequences of SEQ ID
10 NOS 1-16, 18-41, or 43-49.

Fine Mapping of Alpha2/delta to mouse chromosome 9



New alpha2delta




FIGURE #2

Human $\alpha 2\delta 2$ Tissue Distribution




Figure 3. [3 H] Gabapentin binding activity by human $\alpha 2\delta 2$ in transiently transfected Cos 7 cells





FIGURE #4



-1-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT:
(A) NAME: Margaret Ann Johns
(B) STREET:
(C) CITY:
(D) STATE:
10 (E) COUNTRY:
(F) POSTAL CODE (ZIP):
(G) TELEPHONE:
(H) TELEFAX:
- 15 APPLICANT:
(A) NAME: Brian Jay Moldover
(B) STREET:
(C) CITY:
(D) STATE:
20 (E) COUNTRY:
(F) POSTAL CODE (ZIP):
(G) TELEPHONE:
(H) TELEFAX:
- 25 APPLICANT:
(A) NAME: James David Offord
(B) STREET:
(C) CITY:
(D) STATE:
(E) COUNTRY:
30 (F) POSTAL CODE (ZIP):
(G) TELEPHONE:
(H) TELEFAX:
- (ii) TITLE OF INVENTION: Alpha-2/Delta Gene
- 35 (iii) NUMBER OF SEQUENCES: 49
- (iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
40 (B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
- (2) INFORMATION FOR SEQ ID NO: 1:
- 45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
50 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
(A) NAME/KEY: Coding Sequence
(B) LOCATION:
(D) OTHER INFORMATION: $\alpha 2\delta$ -B
- 55 (iii) MOLECULE TYPE: cDNA

-2-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CGGGCAGCGCAGCCCGCAGAGCGCTGCGGCCCGTGCAGCCCCGGAGGCCCTCGCGGAGAAGGCG
5 GCGGCGGAGGAGAGGCCGAGTTACCGCCCGCGCCCGCGCCCCCAACCCCGCGCGCCGCCGCG
CGCCGCCACTGCCCCCCTCCCCGCGGCGCCGATCTTGAATGGAACATGGCGGTGCCGGCTCGG
ACCTGCGGCGCCTCTCGGCCCGGCCAGCGCGACTGCGCGCCCTGGCCCGGCTGCGGCCCCAC
CCTGGCCCGGCACCCGCGCCGACGTCCGGGCCCGCGCCCGCTGTGGTGTCTGCTGCCGCTT
CTACCGCTGCTCGCCGCCCGCGCCTCTGCCCTACAGCTTCCCCAGCAGCACACGATGCAGCAC
10 TGGGCGCGGCTCTGGAGCAGGAGGTCGACGGCGTGATGCGGATTTTGGAGGCTCCAGCAGCTC
CGTGAGATTTACAGGACAACCGAACCTGTTCCGAGGTACAGGAGAATGAGCCTCAGAAGTTGGTG
GAGAAGGTGGCAGGGACATTGAGAGCCTTCTGGACAGGAAGGTGCAGGCCCTGAAGAGACTGGCT
GATGCTGCAGAGAACTTCCAGAAAGCACACCGCTGGCAGGACAACATCAAGGAGGAAGACATCGTG
TACTATGACGCCAAGGCTGACGCTGAGCTGGACGACCTGAGAGTGAGGATGTGGAAGGGGTCT
AAGGCCAGCACCCCTAAGGCTGGACTTCATCGAGGACCCAACTTCAAGAACAGGTCAACTATTCA
15 TACGCGGCTGTACAGATCCCTACGGACATCTACAAAGGCTCCACTGTCATCCTCAATGAGCTCAAC
TGGACAGAGGCCCTGGAGAATGTGTTTATGGAACCGCAGACAAGACCCACACTGCTGTGGCAG
GTCTTCGGCAGCGCCACAGGAGTCACTCGCTACTACCCGGCCACCCCGTGGCGAGCCCCAAGAAG
ATCGACCTGTACGATGTCCGAAGGAGACCTGGTATATCCAGGGGGCTCGTCACCCAAAGACATG
GTCTATCATCGTGGATGTGAGTGGCAGTGTGAGCGGCTGACCTGAAGCTGATGAAGACATCTGTC
20 TGGCAGATGCTGGACACGCTGTCTGATGATGACTATGTGAATGTGGCCTCGTTCAACGAGAAGGCA
CAGCCTGTGTCTGCTTACACACCTGGTGCAGGCCAATGTGCGCAACAAGAAGGTGTTCAAGGAA
GCTGTGCAGGGCATGGTGGCCAAGGGCACCACAGGCTACAAGGCCGGCTTTGAGTATGCCTTTGAC
CAGCTGCAGAACTCCAACATCACTCGGGCCAAGTGAACAAGATGATCATGATGTTACGGATGGT
GGTGAGGACCGCGTGCAGGACGTCTTTGAGAAGTACAATGGCCAAACCGGACGGTGGCGGTGTTT
25 ACTTTCTCCGTGGGGCAGCATAACTATGACGTACACCGCTGCAGTGGATGGCCTGTGCCAACA
GGCTACTATTTTGAATCCCTTCCATCGGAGCCATCCGATCAACACACAGGAATATCTAGATGTG
TTGGGCAGGCCCATGGTGTGGCAGGCAAGGAGGCCAAGCAGGTTCAAGTGGACCAACGTGTATGAG
GATGCACTGGGACTGGGGTTGGTGGTAACAGGACCCCTCCCTGTTTTCAACCTGACACAGGATGGC
CCTGGGGAAGAAGAACCAGCTGATCCTGGGCGTGATGGGCATTGACGTGGCTCTGAATGACATC
30 AAGAGGCTGACCCCAACTACACGCTTGGAGCCAACGGCTATGTGTTGCCATTGACCTGAACGGC
TACGTGTTGCTGCACCCCAATCTCAAGCCCGAGACCACCAACTTCCGGGAGCCTGTGACTCTGGAC
TTCCTGGATGCGGAGCTAGAGGATGAGAACAAGGAAGAGATCCGTGGAGCATGATTGATGGCAAC
AAGGGCCACAAGCAGATCAGAACGTTGGTCAAGTCCCTGGATGAGAGGTACATAGATGAGGTGACA
CGGAACCTACACCTGGGTGCCCTATAAGGAGCACTAACTACAGCCTGGGGCTGGTGTCTCCACCCCTAC
35 AGCACCTTCTACCTCCAAGCCAATCTCAGTGACAGATCCTGCAGGTCAAGTATTTGAGTTCCTG
CTCCCCAGCAGCTTTGAGTCTGAAGGACAGCTTTTCATTGCTCCAGAGAGTACTGCAAGGACCTG
AATGCCTCAGACAACAACACCGAGTTCTTGAAGAACTTTATTGAGCTCATGGAGAAAGTGACTCCA
GACTCCAAGCAGTGCAACAACCTTCTTCTGCACAACCTGATCTTGGACACGGGCATCACGCAGCAG
CTGGTAGAGCGTGTGTGGAGGGACAGGATCTCAACAGTACAGCCTACTGGCCGTGTTCCGCTGCC
40 ACAGACGGTGGCATCACCCGAGTCTTCCCCAACAGGCAAGGAGCTGAGGACTGGACAGAGAACCCTGAG
CCCTTCAATGCCAGCTTCTACCGCCGAGCCTGGATAACCACGGTTATGTCTTCAAGCCCCACAC
CAGGATGCCCTGTTAAGGCCGCTGGAGCTGGAGAATGACACTGTGGGCATCCTCGTCAGCACAGCT
GTGGAGCTCAGCCTAGGCAGGCGCACACTGAGGCCAGCAGTGGTGGCGCTCAAGCTGGACCTAGAG
GCTTGGGCTGAGAAGTTCAAGGTGCTAGCCAGCAACCGTACCCACCAAGACCAGCCTCAGAAGTGC
45 GGCCCCAACAGCCACTGTGAGATGGACTGCGAGGTAAACAATGAGGACTTACTCTGTCTCTCATT
GATGATGGAGGATTCCTGGTGTCTCAAACAGAACCATCAGTGGGACAGGTGGGCAGGTTCTTC
AGTGAGGTGGATGCCAACCTGATGCTGGCACTCTACAATAACTCCTTCTACACCCGCAAGGAGTCC
TATGACTATCAGGCAGCCTGTGCCCTCAGCCCCCTGGCAACCTGGGTGCTGCACCCCGGGGTGTC
TTTGTGCCACCGTTGCAGATTTCTTAACTGGCCTGGTGGACCTCTGCTGCCGCTGTTCCCTG
50 TTCCAGCAGCTTCTCTACGGCCTCATCTACCACAGCTGGTTCCAAGCAGACCCCGCGGAGGCCGAG
GGGAGCCCCGAGACGCGGAGAGCAGCTGCGTCATGAACAGACCCAGTACTACTTGGCTCGGTA
AACGCTCTTACAACGCCATCATGACTGCGGAACTGCTCCAGGCTGTTCCACGCGCAGAGACTG
CTGCTGAGAAGGAGACGCACTGCCAGCGGACGGCCCGGAGCAGTGTGAGCTAGTGCAGAGACCG
55 CGATACCGGAGAGGCCCGCACATCTGCTTCACTACAACGCGACAGAAGATACCTCAGACTGTGGC
CGCGGGGCTCCTTCCCGCGCTCGCTGGGCTCCTGGTCTCCCTGCAACTGCTGCTCCTCCTGGGC
CTGCCGCCCCGGCCGAGCCTCAAGTCTCCTGCCGCTCTCGCCGCTCTGAGCACCTGCCCC
ACCCACCTCCACTCCACCTCACCCGGCTCTTCCGCTTTCCACCTCTGCCCCACACTCCCC
GCCTTAGAGCCTCGTCCCTCCCTCACTGAAGGACCTGAGCTGGCCAGGCCCTGAGAGTCTGGTCTG

-3-

CGCCTTGGGATGGGGAGTCCCAAAGCGGGACGCCGAGGTGTTTGGCACCCAAATCACATCTCACC
TCCGAAGTGTCAAGTGTCCCCAGACCCCTTCTTGCTGCTGGGCTCCCCCAGTGGGATGGGACAG
GGAGGCCACACGCACTGGTGCCAAAACAGGCCCTTGCTGCCGCCCTTCTGGAGGCTGCCTATGT
TGGGGGGGACCTGCCTCAGCTGACCCGGCCTCTGCCCCACCCAAAGCCCAAAGTGGTTTCTGT
5 GAGAATAGTGGAGGAAGGTGAGATGGCCAGTTTGAAGCCTGTGCCTCCCAGCTTAAATCCTAGCAG
GAGAGAGGCTCTGGGGCAGCCCCATGGGCTCCTGCCCTTTTCAGGCCTACAGCCACATCCCCAAG
CCCACCAGGTGTGAGGATAGTACAGTGATACCAGTTTCAGACACTACCCCATATACACCTGGAACA
TTGAGGATGGAACTGGACTCACATTGACATACCCACTGGGGCACACGCACAAACACACACACTA
TGGGGTGGGGTGGGTGTAGGGGCTTACAAAGCCTTACACAGGGCGAGGGGTGGTGGGAGGGTTGG
10 CACCTGCACACTCCATCTCTGCTCACCACCTGCCTCTAATCTGAGCTGCAGCCTGGCTGGTCTC
CCATTTCTAAAGCTGAATGTCAAACAGTGCCAAATGCTGGGGCAGGGGTGAAGAACCCTCTGTCC
CACCCCTAGCCACCACTGTCTCCAAGTGCCCCCTCACCTCTCCAGGTGCTCATTGTAACCATTTT
TCACTAGTGTGAGGCCCCAGTGGGACCACATGCCACTGCCTGCACCTTTGGGAGAGGAACCCCC
ACCAGACATCACCTTTGCCTTAGCAGGGGTGACTTTGTCTCTCCTGGCTGGGCCATCCTTCCGCC
15 AATCTGGCCCTTACACACTCAGGCCTGTGCCCCTCCCTATCTCCTTCCACCCCTACACACACAC
TCCCTGCTTGCAGGAGGCCAACTTCCCTCCCTTGTGAACACACACACACACACACAG
GTGGGGCAGTGGGCACAGCTCTTGCACACCTTCACTTGGTCAATTTCCCCCAAAGGCATCCAGCCT
GGGGGCCAGTGGGGAAGTGAAGGGCAAGGGGATATAGTGATGGGGCTCAGATGGACTGGGAGGAGGG
GGAGGGTGATGCATTAATTAATGGCTTCGTTAATTAATGTCATGTTGCTTGTGCTTTCTCAGTGT
20 GTGTGTGTGGTCCATGCCCACTGCTGGTGCCAGGGTGGGTGTCCATGTGCACCCGGCTGGATGCC
AGCTGTGTCCTTCGGGGCGTGCGTGAAGTGTAGTGTAGTCAAGTGTCAATGGAGAATATAAAC
ATATACAGAAAAATATATATTTAAGTTTAAAAAACAGAAAAACAGACAAAACAATCCCCATCAGG
TAGCTGTCTAACCCCACTGGGTCTAATCCTTCTCATTACCCACCCGACCTGGCTGCCCTCACC
TTGGGCTGGGGGACTGGGGGCCATTTCTTTTCTGCCCCTTTTTTTGTGTTTCTATTTGTACA
25 GACAAGTTGGAAAAACAACAGCGACAAAAAGTCAAGAACTTTGTAAAATATCGTGTGTGTGATT
CCTTGTAATAATTTTCAAATGGTTTATTACAGAAGATCAGTTATTAAATAATGTTTCATATTTCA
CTTC

(2) INFORMATION FOR SEQ ID NO: 2:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

35

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

40

(D) OTHER INFORMATION: $\alpha 28$ -B

(iii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

45

50

55

MAVPARTCGASRPGPARTARWPGPCGPHPGPTRRPTSGPPRPLWLLLPLLLAAPGASAYSFPQ
QHTMQHWARRLEQEVGVMRIFGGVQQLREIYKDNRLFEVQENEPQKLVEKVAGDIESLLDRKVQ
ALKRLADAENFQKAHRWQDNIKEEDIVYYDAKADAELDDPESEDVERGSKASTLRDLDFIEDPNFK
NKVNYSYAAVQIPTDIYKGSTVILNELNWTEALENVFMENRRQDPTLLWQVFGSATGVTRYYPATP
WRAPKKIDLYDVRPPWYIQGASSPKDMVIIVDVSGSVSGLTLKLMKTSVCEMLDLSDDDYVNV
SFNEKAQPVSCFTHLVQANVRNKKVFKEAVQGMVAKGTTGYKAGFEYAFDQLQNSNITRANCNMI
MMFTDGGEDRVQDVFEKYNWPNRTVRVFTFSVGQHNVDVTPQWMAKNGYFEIPIGAI RINT
QEYLDVLGRPMVLAGEAKQVQWNTNVEDALGLVVTGTLPVFNLTQDGPGEKKQNLILGVMGID
VALNDIKRLTPNYTLGANGYVFAIDLNGYVLLHPNLKPQTTFREPVTLDLDAELEDENKEEIRR
SMIDGNKGHKQIRTLVKSLDERYIDEVTRNYTWVPIRSTNYSGLVLPYSTFYLOANLSDQILQV
KYFEFLLPSSFESEGHVFIAPREYCKDLNASDNNTFLKNFIELMEKVT PDSKQCNFLLHNLILD
TGITQQLVERVWRDQDLNTYSLLAVFAATDGGITRVFPNKAEDWTENPEPFNASFYRRSLDNHGY
VFKPPHQDALLRPLELENDTVGILVSTAVELSLGRRTLRAVVGVKLDLEAWAEKFKVLASNRTHQ

-4-

5 DQPQKCGPNSHCEMDCEVNNEDLLCVLIDDGGFLVLSNQNHQWDQVGRFFSEVDANLMLALYNNF
YTRKESYDYQAACAPQPPGNLGAAPRGVFPVTVADFLNLAWWTSAAAWSLFQQLLYGLIYHSWFQA
DPAEAEGLSPETRESSVMKQTQYYFGSVNASYNALIDCGNCSRLFHAQRLTNTNLLFVVAEKPLCS
QCEAGRLLQKETHCPADGPEQCELVQRPRYRRGPHICFDYNATEDTSDCGRGASFPPSLGVLVSLQ
LLLLLGLPPRPQPQVLVHASRRL

(2) INFORMATION FOR SEQ ID NO: 3:

10 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION:
- (D) OTHER INFORMATION: $\alpha 28$ -C

20 (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TACTATAGGGCGGCCGCGAATTCGGCAGAGGGCGCGGAGCGGAGCAGGCAGCCCCGCGCGCTC
25 GCCCACCGCCCGCTCCGCGCAGCTCCCCGCGGCCGCTCTCGTCGCCGCGCAGCGGGCGGTTCGGA
GGGAGCCCCAGCATGGCCGGGCGGGCTCGCCGCGCCGCGCTCCCGGGGGCCTCGGCGCTTCTCG
CTGCCGCGCTTCTCTACGCGCGCTGGGGACGTGGTGCGCTCGGAGCAGCAGATACCGCTCTCCG
TGGTGAAGCTCTGGGCTCGGCTTTTGGTGGGAGATAAAATCCATTGCTGCTAAGTACTCCGGTT
CCCAGCTTCTGCAAAAGAAATACAAAGAGTATGAGAAAGACGTTGCCATAGAAGAAATGATGGCC
TCCAACTGGTAAAGAAGCTGGCAAAGACATGGAAGAGATGTTTCAAGAAGTCTGAGGCCGTCA
30 GCGCTCTGGTGGAGGCTGCAGAAGAAGCACACCTGAAACATGAATTTGATGCAGACTTACAGTATG
AATACTTCAATGCTGTGCTGATAAATGAAAGGGACAAAGACGGGAATTTTGGAGCTGGGAAAGG
AATTCATCTTAGCCCCAAATGACCATTTTAATAATTTGCCTGTGAACATCAGTCTAAGTGACGTCC
AAGTACCAACGAACATGTACAACAAAGACCCTGCAATTGTCAATGGGGTTTATTGGTCTGAATCTC
TAAACAAAGTTTTTGTAGATAACTTTGACCGTGACCCATCTCTCATATGGCAGTACTTTGGAAGTG
35 CAAAGGGCTTTTTTAGGCAGTATCCGGGGATTAAATGGGAACCAGATGAGAATGGAGTCATTGCCT
TCGACTGCAGGAACCGAAAATGGTACATCCAGGCAGCAACTTCTCCGAAAGACGTGGTCATTTAG
TTGACGTCACTGGCAGCATGAAAGGACTCCGTCTGACTATCGCGAAGCAAACAGTCTCATCCATTT
TGGATACACTTGGGGATGATGACTTCTTCAACATAATTGCTTATAATGAGGAGCTTCACTATGTGG
AACCTTGCTGAATGGAACCTTTGGTGAAGCCGACAGGACAAACAAAGAGCACTTCAGGGAGCATC
40 TGGACAACTTTTCGCCAAAGGAATTGGAATGTTGGATATAGCTCTGAATGAGGCCCTTCAACATTC
TGAGTGATTTCAACCACACGGGACAAGGAAGTATCTGCAGTCAGGCCATCATGCTCATAACTGATG
GGGCGGTGGACACCTATGATACAATCTTTCAAAATACAATTGGCCAGATCGAAAGGTTTCGCATCT
TCACATACCTCATTGGACGAGAGGCTGCGTTTGCAGACAATCTAAAGTGGATGGCCTGTGCCAACA
AAGGATTTTTTACCCAGATCTCCACCTTGGCTGATGTGCAGGAGAATGTCATGGAATACCTTCACG
45 TGCTTAGCCGGCCCCAAAGTCATCGACCAGGAGCATGATGTGGTGTGGACCGAAGCTTACATTGACA
GCACTCTGACTGATGATCAGGGCCCCGCTCTGATGACCACTGTAGCCATGCCTGTGTTTAGTAAGC
AGAACGAAACCAGATCGAAGGGCATTCTTCTGGGAGTGGTTGGCACAGATGTCCAGTGAAAGAAC
TTCTGAAGACCATCCCCAAATACAAGTTAGGGATTACCGGTTATGCCTTTGCAATCACAAATATG
GRTATATCCTGACGCATCCGGAACCTCAGGCTGCTGTACGAAGAAGGAAAAAGCGAAGGAAACCTA
50 ACTATAGTAGCGTTGACCTCTCTGAGGTGGAGTGGGAAGACCGAGATGACGTGTTGAGAAATGCTA
TGGTGAATCGAAAGACGGGGAGTTTTCATGGAGGTGAAGAAGACAGTGGACAAAGGGAAACGGG
TTTTGGTGATGACAAATGACTACTATTATACAGACATCAAGGGTACTCCTTTCAGTTTAGGTGTGG
CGCTTTCCAGAGGTCATGGGAAATATTTCTCCGAGGGAATGTAACCATCGAAGAAGGCCTGCATG
ACTTAGAACATCCCGATGTGTCTTGGCAGATGAATGGTCTACTGCAACACTGACCTACACCCTG
55 AGCACCGCCATCTGTCTCAGTTAGAAGCGATTAGCTCTACCTAAAAGGCAAGAACCTCTGCTCC
AGTGTGATAAGAATTGATCCAAGAAGTCCTTTTGACGCGGTGGTGAGTGCCCCCATGAAGCGT
ATTGGACCAGCCTGGCCCTCAACAAATCTGAAAATCTGACAAGGGCGTGGAGGTTGCCTTCTCTCG

-5-

5 GCACTCGCACGGGCTCTCCAGAATCAACCTGTTTGTGCGGGCTGAGCAGCTCACCAATCAGGACT
TCCTGAAAGCTGGCGACAAGGAGAACATTTTAAACGCAGACCATTTCCCTCTCTGGTACCGAAGAG
CCGCTGAGCAGATTCCAGGGAGCTTCGTCTACTCGATCCCATTAGCAGCTGGACCAGTCAATAAAA
GCAATGTGGTGACAGCAAGTACATCCATCCAGCTCCTGGATGAACGGAAATCTCCTGTGGTGGCAG
10 CTGTAGGCATTGAGATGAACTTGAATTTTCCAAAGGAAGTTCTGGACTGCCAGCAGACAGTGTG
CTTCCCTGGATGGCAAATGCTCCATCAGCTGTGATGATGAGACTGTGAATGTTACCTCATAGACA
ATAATGGATTTATTTTGGTGTCTGAAGACTACACACAGACTGGAGACTTTTTTGGTGAGATCGAGG
GAGCTGTGATGAACAAATTGCTAACAATGGGCTCCTTTAAAAGAATTACCCTTTTACTACCAAG
CCATGTGTAGAGCCAACAAGGAAAGCAGCGATGGCGCCCATGGCCTCCTGGATCCTTATAATGCCT
15 TCCTCTCTGCAGTAAATGGATCATGACAGAACTTGTCTTGTTCCTGGTGGAAATTTAACCTCTGCA
GTTGGTGGCACTCCGATATGACAGCTAAAGCCCAGAAATTGAAACAGACCCTGGAGCCTTGTGATA
CTGAATATCCAGCATTTCGTCTCTGAGCGCACCATCAAGGAGACTACAGGGAATATTGCTTGTGAAG
ACTGCTCCAAGTCCTTTGTCTATCCAGCAAATCCCAAGCAGCAACCTGTTTCATGGTGGTGGTGACA
GCAGCTGCCCTCTGTGAATCTGTGGCCCCCATCACCATGGCACCCATTGAAATCAGGTATAATGAAT
20 CCCTTAAGTGTGAACGTCTAAAGGGCCAGAAGATCAGAAGGCGCCAGAAATCTTGTATGGCTTCC
ATCCTGAGGAGAATGCAAGGGAGTGTGGGGTGGCGCCGAGTCTCCAAGCCAGACAGTCCTCCTTC
TGCTCCTCTGCTTTTGTGCTCTTCTCAAGGTGACACTGACTGAGATGTTCTCTTACTGACTGAG
ATGTTCTCTTGGCATGCTAAATCATGGATAAACTGTGAACCAAATATGGTGCAACATACGAGACA
TGAATATAGTCCAACCATCAGCATCTCATCATGATTTTAACTGTGCGTGATATAAACTCTTAAAG
25 ATATGTTGACAAAAGTTATCTATCATCTTTTACTTTGCCAGTCATGCAATGTGAGTTTGCCAC
ATGATAATCACCCTTCATCAGAAATGGGACCGCAAGTGGTAGGCAGTGTCCCTTCTGCTTGAACC
TATTGAAACCAATTTAAACTGTGTACTTTTTAAATAAAGTATATTAATCATAAAAA
AAAAAA

25

(2) INFORMATION FOR SEQ ID NO: 4:

- 30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
35 (ix) FEATURE:
(A) NAME/KEY: Coding Sequence
(B) LOCATION:
(D) OTHER INFORMATION: $\alpha 2\delta$ -D
40 (iii) MOLECULE TYPE: cDNA

40

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
CCATGCCTGCAACTCCCAACTTCCTCGCAAACCCAGCTCCAGCAGCCGCTGGATTCCCTCCAGC
CAATGCCCCGTGGCCTGGGCCTTTGTGCAAGAACCTCGGCCCTCCTGTGGCTGCTGCTTCTAGGCA
CCTCCCTGTCCCCTGCGTGGGGACAGGCCAAGATTCTCTGGAACAGTGAAGCTATGGCTGACA
45 CCTTCGGCGGGGACCTGTATAACACTGTGACCAAATACTCAGGCTCTCTTCTGTCAGAAGAAGT
ACAAGGATGTGGAGTCCAGTCTGAAGATCGAGGAGGTGGATGGCTGGAGCTGGTGAGGAAGTTCT
CAGAGGACATGGAGAACATGCTGCGGAGGAAAGTCGAGGCGGTCCAGAATCTGGTGGAGCTGCCG
AGGAGGCCGACCTGAACCACGAATTCATGAATCCCTGGTGTTGACTATTACAACCTCGGTCTGA
TCAACGAGAGGGACGAGAAGGGCAACTTCGTGGAGCTGGGCGCCGAGTTCCTCCTGGAGTCCAATG
50 CTCATTTCAGCAACCTGCCGGTGAACACCTCCATCAGCAGCGTGCAGCTGCCACCAACGTGTACA
ACAAAGACCCAGATATTTAAATGGAGTCTACATGTCTGAAGCCTTGAATGCTGTCTTCGTGGAGA
ACTTCCAGAGAGACCCAAACGTTGACCTGGCAATATTTTGGCAGTGCAACTGGATTCTTCAGGATCT
ATCCAGGTATAAAATGGACACCTGATGAGAATGGAGTCATTACTTTTACTGCCGAAACCGCGGCT
GGTACATTCAAGCTGCTACTTCTCCAAGGACATAGTGATTTTGGTGGACGTGAGCGGCAGTATGA
55 AGGGGCTGAGGATGACTATTGCCAAGCACACCATCACCACCATCTTGGACACCCTGGGGGAGAATG
ACTTCGTTAATATCATAGCGTACAATGACTACGTCCATTACATCGAGCCTTGTTTTAAAGGATCC
TCGTCCAGGCGGACCGAGACAATCGAGAGCATTTCAAACCTGCTGGTGGAGGAGTTGATGGTCAAAG

-6-

GTGTGGGGGTCGTGGACCAAGCCCTGAGAGAAGCCTTCCAGATCCTGAAGCAGTTCCAAGAGGCCA
AGCAAGGAAGCCTCTGCAACCAGGCCATCATGCTCATCAGCGACGGCGCCCTGGAGGACTACGAGC
CGGTGTTTGAGAAGTATAACTGGCCAGACTGTAAGGTCGAGTTTTCACCTTACCTCATTGGGAGAG
AAGTGTCTTTTGTGACCGCATGAAGTGGATTGCATGCAACAACAAAGGCTACTACACGCAGATCT
5 CAACGCTGGCGGACACCCAGGAGAACGTGATGGAATACCTGCACGTGCTCAGCCGCCCCATGGTCA
TCAACCACGACCACGACATCATCTGGACAGAGGCCTACATGGACAGCAAGCTCCTCAGCTCGCAGG
CTCAGAGCCTGACACTGCTCACCCTGTGGCCATGCCAGTCTTCAGCAAGAAGAACGAAACGCGAT
CCCATGGCATTCTCCTGGGTGTGGTGGGCTCAGATGTGGCCCTGAGAGAGCTGATGAAGCTGGCGC
CCCGGTACAAGCTTGGAGTGCACGGATACGCCCTTCTGAACACCAACAATGGCTACATCCTCTCCC
10 ATCCCGACCTCCGGCCCCCTGTACAGAGAGGGGAAGAACTAAAACCCAAACCTAACTACAACAGTG
TGGATCTCTCCGAAGTGGAGTGGGAAGACCAGGCTGAATCTCTGAGAACAGCCATGATCAATAGGG
AAACAGGTACTCTCTCGATGGATGTGAAGGTTCCGATGGATAAAGGGAAGCGAGTTCTTTTCTCTGA
CCAATGACTACTTCTTCACGGACATCAGCGACACCCCTTTCAGTTTGGGGGTGGTGTCTCCCGGG
GCCACGGAGAATACATCCTTCTGGGGAACACGTCTGTGGAAGAAGGCCTGCATGACTTGCTTACC
15 CAGACCTGGCCCTGGCCGGTACTGGATCTACTGCATCACAGATATTGACCAGACACCCGGAAGC
TCAGCAGCTAGAGGCCATGATCCGCTTCTCACCAGGAAGGACCCAGACCTGGAGTGGACGAGG
AGCTGGTCCGGGAGGTGCTGTTTACGCGGTGGTGACAGCCCCATGGAAGCCTACTGGACAGCGC
TGGCCCTCAACATGTCCGAGGAGTCTGAACACGTGGTGGACATGGCCTTCTGGGCACCCGGGCTG
GCCTCCTGAGAAGCAGCTTGTTCGTGGGCTCCGAGAAGGTCTCCGACAGGAAGTTCCTGACACCTG
20 AGGACGAGGCCAGCGTGTTCACCTGGACCGCTTCCCGCTGTGGTACCGCCAGGCCTCAGAGCATC
CTGCTGGCAGCTTCGTCTTCAACCTCCGCTGGGCAGAAGGACCAGAAAGTGGGGGTGAACCCATGG
TGGTGACGGCAAGCACAGCTGTGGCGGTGACCGTGGACAAGAGGACAGCCATTGCTGCAGCCGCGG
GCGTCCAAATGAAGCTGGAATTCTCCAGCGCAAATTCTGGGCGGCAACGCGGAGTGCAGCACTG
TGGATGGGCGGTGCACACAGAGCTGCGAGGACAGTGCATCTGGACTGCTTCGTATCGACAACACG
25 GGTTCATTCTGATCTCCAAGAGGTCCCGAGAGACGGGAAGATTCTGGGGGAGGTGGATGGTGTCTG
TCCTGACCCAGCTGCTCAGCATGGGGGTGTTCAGCCAAGTGACTATGTATGACTATCAGGCCATGT
GCAAACCTCGAGTCACCACCACAGTGCAGCCAGCCCTGGTCAGCCCAATTTCTGCCTTCTTGA
CGGCGACCAAGTGGCTGCTGCAGGAGCTGGTGTCTTCTGCTGGAGTGGAGTGTCTGGGGCTCCT
GGTACGACAGAGGGGCGGAGGCCAAAAGTGTCTTCCATCACTCCCAAAACACAAGAAGCAGGACC
30 CGCTGCAGCCCTGCGACACGGAGTACCCCGTGTTCGTGTACCGCCGCGCATCCGGGAGGCCAACG
GGATCGTGGAGTGCGGGGCCCTGCCAGAAGGTATTTGTGGTGCAGCAGATTCCCAACAGTAACCTCC
TCCTCCTGGTGACAGACCCACCTGTGACTGCAGCATCTTCCACCAGTGTCTGCAGGAGGCGACAG
AAGTCAAATATAATGCCTCTGTCAAATGTGACCGGATGCGCTCCAGAAGCTCCGCGGCGACCCAG
ACTCCTGCCACGCCTTCCATCCAGAGGAGAATGCCAGGACTGCGGCGGCGCCTCGGACACCTCAG
35 CCTCGCGCGCCCTACTCCTGCTGCCTGTGTGTGCTGGGGGCTACTGCCCCAATCCTGCGGTGAC
ACCACCCAGCCTGACCTGTGTTTGGCAAGGTGATCCTTCCAGAGCCATCCCAAAAGTCAGCACT
GACATGGGATGCAGCTAACTGCAGTGTGGGTGCGCCCCAGGCCAACGCTCCTCTCAATCCTGGGCTG
GTGGCCCCCTGGCTCCGGAGAATGCTGGATGGAACAGGAACCAATCACCTGGCACCACTTTCAAGA
TGCTTCATGGTGGCCGGTACCATCTGCCCTAGGTCTCAACATGAGCATACTTCTGACCTAACCTTC
40 CTGTCTCCTCTTCGGGAAGCCAGCGTGAGCTCAGCTTGGACCAAGACAAAATAATTTAGTTCTTCC
TGTAATCCAGAGTCCAGACCCAGCCAAGAAAGGTCAGTTGTTTCTGACCTTTCTGTCTGGAGTGG
TCTCTGGTAGAACCAAGGACTTCTGGGTACTGAGAAGCAGCAGCAGAATGAGGCCAAATGCAGAG
ATGAGGCTAAGGCAAGAAATATGCCCAACTAAAGCATAGATTCCCAAAAGTGAGGCTCATGGTGGG
AGGCCACTCACCTTCTAGCTGCTGCTCGAAAAGGTTTGTACTGTGTGGGGTGGGGGTGGGTAA
45 GGGAAATGGTCAAGACTGAGAAAGGAATGAAATCCATTCAGGAAATATCGACAGGGCTACACGTGAT
GTCCCCAAACTGCTGCTATTGAAGAACTTCCCAAACTTCTTTACAAAGCCCTAAAGGAAAGTTTG
CATCTATGAAAAGCCAATAGGCTGAGACATCCAATTGCTGCATGGAATTTGATGTACATTCAGGGG
ACGGCAAAAATAGCTGTAAAATAGTAAAAAGAGCAGTGGTTGTGCTCTTTCTGGCCAATGATTT
ACAAAAGAATCTACTTGACTCTGTCCCTGGAGTGAAATCCTTAGGGTTGGAACCTTGTGGGAACATT
50 CCAACTTGCTAAGCAGGGTCCACTGGGAGGGAAGCTCTATCTGGGAACCTCACCCACGCGACACA
CATCTCCCCCAGGGTCCCAAGGCCCGCAGCTTCTCCCCCGACCAAAACCCCAAGACCTGGATCCC
AGGAGACAACAGTCTCCACATGAGAGCAACATTAAGGGCAAAGCCATGGAGAAATGTGGGAGAGGC
CGGCTCAAATCTTTTCATTAAACAAACCCAGTGATGGGTATGGACAGCATGCAGGGCTTTTGGG
GCGCTTCCCCCGCTCCTCCATCACCCCTCAGCCTCCACACTTCAAAGTTCAAAGTTCAGGCTGTT
55 AAGTTTCTACCAGCAAATAGCCCTAAGTTCCTCTAGAGTAGGCCAAATGCCAACTCTGTAAAC
ACACTTACATTATCGGTTACAGAATGTACTCTTACCATCATGTCTTGCAACAACCCCTGTGAGGGC
AGTATTAAATGCCCCCTTACAGCAGAAGACACTGCAGCTCGAAGACAGCTTAAGTGGCAGAATAATG
CTAGAACAGCTAAGGTTTACATGTACCAAAATAACATGTTTCAGCTCATTCCATCCTCACAACAGCC
CCCTGAAAGTGGGTACTATCATTAGTCCCATGTTATAGAACTGCAGCAGAGTTGAAAATTGCCTC

-7-

CAAATTACCGGAAGAGTGTATGAAGATTGAATGTGATGTATTACGTAACATGCTTGAAACTGCCT
GGCATATACTAAACGCTAAATAAATACATGCTAACTGCAAAAAAAAAAAAAAAAAAAAA

5 (2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

10 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY:

15 (B) LOCATION:

(D) OTHER INFORMATION: α 2 δ -C

(iii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

20 MAGPGSPRRASRGASALLAAALLYAALGDVVRSEQQIPLSVVKLWASAFGGEIKSIAAKYSGSQLL
QKKYKEYEKDVAIEEIDGLQLVKKLAKNMEEMFHHKSEAVRRLVEAAEEAHLKHEFDADLQYEFN
AVLINERDKDGNFLELGKEFILAPNDHFNNLPVNISLSDVQVPTNMYNKDPAIVNGVYWSES LNKV
FVDNFDRDPSLIWQYFGSAKGFFRQYPGIKWEPDENGVIADFCDNRNKWYIQAATSPKDVVILVDVS
25 GSMKGLRLTIKQTVSSILDTLGDDDDFFNIIAYNEELHYVEPCLNGTLVQADRTNKEHFREHLDKL
FAKGIGMLDIALNEAFNLSDFNHTGQGSICSQAIMLITDGAVDITYDTIFAKYNWPD RKVRIFTYL
IGREAAAFADNLKWMACANKGFFTQISTLADVQENVMEYLHVLSRPKVIDQEHVWTEAYIDSTLT
DDQGPVLMTTVAMPVFSKQNETRSKGILLGVGTDPVKELLKTIPKYKLGIGHYAFAITNNGYIL
THPELRLLYEEGKKRRKPNYSSVDLSEVEWEDRDDVLRNAMVNRTKGKFSMEVKKTVDKGKRVLM
TNDYYYTIDIKGTFPFSLGVALSRGHGKYFFRGNVTIEEGLHDLEHPDVSLADEWSYCN TDLHPEHRH
30 LSQLEAIKLYLKGEFLQCDKELIQEVLFDAVVSAPIEAYWTSALNKSSENSDKGVEVAFLGTRT
GLSRINLFVGAEQLTNQDFLKAGDKENIFNADHFPLWYRRAAEQIPGSFVYSIPFSTGPNKSNVV
TASTSIQLLDERKSPVVAAVGIQMKLEFFQRKFWTASRQCASLDGKCSISCDDET VNCYLIDNNGF
ILVSEDTQTGDFGGEIEGAVMNKLLTMGSFKRITLYDYQAMCRANKES SDGAHGLLDPYNAFLSA
VKWIMTELVLFLVEFNLCSSWWHSDMTAKAQLKQTLPCDTEYPAFVSERTIKETTGN IACEDCSK
35 SFVQQIPSSNLFMVVVDSSCLCESVAPITMAPIEIRYNESLK CERLKAQKIRRRPESCHGFHPPEE
NARECGGAPSLQAQTVLLLLPLLLMLFSR

40 (2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

45 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY:

50 (B) LOCATION:

(D) OTHER INFORMATION: α 2 δ -D

(iii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

-8-

MPATPNFLANPSSSSRWIPLQPMVAVAFVQKTSALLWLLLGTSLSPA WGQAKI PLETVKLWADT
 FGGDLVNTVTKYSGSLLLQKKYKDVESLKI EEVDGLELVRKFSEDMENMLRRKVEAVQNLVEAAE
 EADLNHEFNESLVFDYNSVLINERDEKGNFVELGAEFLLESNAHFSNLPVNTSISSVQLPTNVYN
 KDPDILNGVYMSEALNAVVENFQRPDPTLTWQYFGSATGFFRIYPGIKWTPDENGVITFDCRNRGW
 5 YIQAATSPKDIVILVDVSGSMKGLRMTIAKHTITITLDTLGENDFVNIIAYNDYVHYIEPCFKGIL
 VQADRDNREHFKLLVEELMVKGVGVDQALREAFQILKQFQEAQGS LCNQAIMLISDGAVEDYEP
 VFEEKYNWPDCKVRVFTYILIGREVSFADRMKWIACNNKGYTQISTLADTQENVMEYLHVLSRPMVI
 NHDHDIWTEAYMDSKLLSSQAQSLTLLTTVAMPVFSKKNETRSHGILLGVVGS DVALRELMKLAP
 10 RYKLG VHGYAFLNTNNGYILSHPDRLRPLYREGKKLKPKNYNSVDLSEVEWEDQAESLRTAMINRE
 TGTLSMDVKVPMDKGKRVLF LTNDYFFTDI SDTPFSLGVLSRGHGEYILLGNTSVEEGLHDL LHP
 DLALAGDWIYCITDIDPDHRKLSQLEAMIRFLTRKDPDLECDEELVREVLFD AVVTAPMEAYWTAL
 ALNMSESEHVVDMAFLGTRAGLLRSSLFVGSEKVS DRKFLTPEDEASVFTLDRFPLWYRQASEHP
 AGSFVFNLRWAEGPESAGEPMVVTASTAVAVTVDKRTAIAAAAGVQMKLEFLQRKFWAATRQCSTV
 15 DGPCTQSCEDSDLD CFVIDNNGFILISKRSRETGRFLGEVDGAVLTQLLSMGVFSQVTMYDYQAMC
 KPSSHHHSAAQPLVSPISAFLTATRWLLQELVLFLEWSVWGSWYDRGAEAKSVFHHSHKHKKQDP
 LQPCDTEYPVFVYQPAIREANGIVECGPCQKVFVVQIIPNSNLLLVT DPTCDCSI FPPVLQEATE
 VKYNASVKCDRMRSQKLRRRPDSCHAFHPEENAQDCGGASDTSAS PPLLLL PVCAGWLLPQLLR

20

(2) INFORMATION FOR SEQ ID NO: 7

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION:

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

AGGATGGCCCTGGGGAAAAGAAGA

(2) INFORMATION FOR SEQ ID NO: 8

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION: 3' primer for $\alpha 2\delta$ -B

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

-9-

ATCATCAATGAGGACACAGA

(2) INFORMATION FOR SEQ ID NO: 9

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
10 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION: 5' primers used for RT-PCR of $\alpha 2\delta$ -C
15 (iii) MOLECULE TYPE: cDNA
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
AGAACGAAACCAGATCGAAG

20 (2) INFORMATION FOR SEQ ID NO: 10

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
25 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
30 (B) LOCATION:
 (D) OTHER INFORMATION: 3' primer used for RT-PCR of $\alpha 2\delta$ -C
 (iii) MOLECULE TYPE: cDNA
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
35 CGATTACCATAGCATTCTC

(2) INFORMATION FOR SEQ ID NO: 11

- 40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: cDNA
45 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:

-10-

(D) OTHER INFORMATION: primer for $\alpha 2\delta$ -C

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

5 CTACCAAGCCATGTGTA

(2) INFORMATION FOR SEQ ID NO: 12

(i) SEQUENCE CHARACTERISTICS:

10

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

15

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 5' primer to amplify mouse $\alpha 2\delta$ -C

20

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

AGAACGAAACTAGGTCAAAG

(2) INFORMATION FOR SEQ ID NO: 13

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

30

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

35

(D) OTHER INFORMATION: 3' primer to amplify mouse $\alpha 2\delta$ -C

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CGATTIACCATGGCATTTTCGT

40

(2) INFORMATION FOR SEQ ID NO: 14

(i) SEQUENCE CHARACTERISTICS:

45

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

-11-

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

5 (D) OTHER INFORMATION: rat sequence for $\alpha 2\delta$ -C

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

10 GATTCTTCTGGGTGTGGTTGGCACAGATGTCCCAGTAAAAGAGCTTCTGAAGACCATCCCCAAATA
CAAGTTAGGAATTCATGGTTATGCCTTTGCCATCACGAATAATGGATACATCTTGACACACCCGGA
GCTCAGGCCCTGTATGAAGAAGGGAAAAAGCGAAGGAAGCCTAATTACAGTAGTGTGGATCTCTC
GGAAGTCGAGTGGGAAGATCGGGATGATGTGTACGAAATGCCATGGTAAATCGAC

15 (2) INFORMATION FOR SEQ ID NO: 15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

25 (D) OTHER INFORMATION: (1690-1761) $\alpha 2\delta$ -D, human splice
variant

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

30 CCATGCCTGCAACTCCCAACTTCCTCGCAAACCCAGCTCCAGCAGCCGCTGGATTCCCCTCCAGC
CAATGCCCCGTGGCCTGGGCCTTTGTGAGAAGACCTCGGCCCTCCTGTGGCTGCTGCTTCTAGGCA
CCTCCCTGTCCCCCTGCGTGGGGACAGGCCAAGATTCTCTGGAAACAGTGAAGCTATGGGCTGACA
CCTTCGGCGGGGACCTGTATAACACTGTGACCAATACTCAGGCTCTCTCTTGCTGCAGAAGAAGT
35 ACAAGGATGTGGAGTCCAGTCTGAAGATCGAGGAGGTGGATGGCTTGGAGCTGGTGAGGAAGTTCT
CAGAGGACATGGAGAACATGCTGCGGAGGAAAGTCAGGCGGTCCAGAATCTGGTGGAAGCTGCCG
AGGAGGCCGACCTGAACCACGAATTCAATGAATCCCTGGTGTTGCGACTATTACAACCTCGGTCTGA
TCAACGAGAGGGACGAGAAGGGCAACTTCGTGGAGCTGGGCGCCGAGTTCCTCCTGGAGTCCAATG
CTCACTTCAGCAACCTGCCGGTGAACACCTCCATCAGCAGCGTGAGCTGCCACCAACGTGTACA
ACAAAGACCCAGATATTTTAAATGGAGTCTACATGTCTGAAGCCTGAATGCTGTCTTCGTGGAGA
40 ACTTCAGAGAGACCCAACGTTGACCTGGCAATATTTTGGCAGTGCAACTGGATTCTTCAGGATCT
ATCCAGGTATAAAATGGACACCTGATGAGAATGGAGTCATTACTTTTGAAGTCCGAAACCGCGGCT
GGTACATTCAAGCTGCTACTTCTCCCAAGGACATAGTGATTTTGGTGAGCTGAGCGGCAGTATGA
AGGGGCTGAGGATGACTATTGCCAAGCACACCATCACCACCATCTTGGACACCCCTGGGGGAGAATG
ACTTCGTTAATATCATAGCGTACAATGACTACGTCCATTACATCGAGCCTTGTTTTAAAGGGATCC
45 TCGTCCAGGCGGACCGAGACAATCGAGAGCATTCAAACCTGCTGGTGGAGGAGTTGATGGTCAAAG
GTGTGGGGGTGCTGGACCAAGCCCTGAGAGAAGCCCTCCAGATCCTGAAGCAGTTCCAAGAGGCCA
AGCAAGGAAGCCTCTGCAACCAGGCCATCATGCTCATCAGCGACGGCGCCGTGGAGGACTACGAGC
CGGTGTTTGAAGAATATACTGGCCAGACTGTAAGTCCGAGTTTCACTTACCTCATTGGGAGAG
AAGTGCTTTTTGCTGACCGCATGAAGTGGATTGCATGCAACAACAAAGGCTACTACACGCAGATCT
50 CAACGCTGGCGGACACCCAGGAGAACGTGATGGAATACCTGCACGTGCTCAGCCGCCCCATGGTCA
TCAACCACGACCACGACATCATCTGGACAGAGGCCCTACATGGACAGCAAGCTCCTCAGCTCGCAGG

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
5 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
10 (D) OTHER INFORMATION: human variant $\alpha 2\delta$ -D, EDGE screen
 (iii) MOLECULE TYPE: cDNA
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
15 CCATGCCTGCAACTCCCAACTTCCTCGCAAACCCAGCTCCAGCAGCCGCTGGATTCCCCTCCAGC
 CAATGCCCTGGCCTGGCCCTTTGTGCAGAAGACCTCGGCCCTCCTGTGGCTGCTGCTTCTAGGCA
 CCTCCCTGTCCCCTGCGTGGGGACAGGCCAAGATTCTCTGGAAACAGTGAAGCTATGGGCTGACA
 CCTTCGGCGGGGACCTGTATAACACTGTGACCAAATACTCAGGCTCTCTCTTGCTGCAGAAGAAGT
 ACAAGGATGTGGAGTCCAGTCTGAAGATCGAGGAGGTGGATGGCTTGGAGCTGGTGAGGAAGTTCT
 CAGAGGACATGGAGAACATGCTGCGGAGGAAAGTCGAGGCGGTCCAGAATCTGGTGGAAGCTGCCG
20 AGGAGGCCGACCTGAACCACGAATTCAATGAATCCCTGGTGTTCGACTATTACAACCTCGGTCTGA
 TCAACGAGAGGGGACGAGAAGGGCAACTTCGTGGAGCTGGGCGCCGAGTTCCTCTGGAGTCCAATG
 CTCACTTCAGCAACCTGCCGGTGAACACCTCCATCAGCAGCGTGCAGCTGCCACCAACGTGTACA
 ACAAAGACCCAGATATTTTAAATGGAGTGTACATGTCTGAAGCCTTGAATGCTGTCTTCGTGGAGA
 ACTTCCAGAGAGACCCAACGTTGACCTGGCAATATTTTGGCAGTGCAACTGGATTCTTCAGGATCT
25 ATCCAGGTATAAAATGGACACCTGATGAGAATGGAGTCATTACTTTTGAAGTCCGAAACCGCGGCT
 GGTACATTCAAGCTGCTACTTCTCCCAAGGACATAGTGATTTGGTGGACGTGAGCGGCAGTATGA
 AGGGGCTGAGGATGACTATTGCCAAGCACACCATCACCACCATCTTGGACACCCTGGGGGAGAATG
 ACTTCRTTAATATCATAGCGTACAATGACTACGTCCATTACATCGAGCCTTGTTTTAAAGGGATCC
 TCGTCCAGGCGGACCGAGACAATCGAGAGCATTTCAAAGTGTGGTGGAGGAGTTGATGGTCAAAG
30 GTGTGGGGGTCTGTGGACCAAGCCCTGAGAGAAGCCCTCCAGATCCTGAAGCAGTTCCTCAAGAGGCCA
 AGCAAGGAAGCCTCTGCAACCAGGCCATCATGCTCATCAGCGACGGCGCCGTGGAGGACTACGAGC
 CGGTGTTTGAGAAGTATAACTGGCCAGACTGTAAGGTCCGAGTTTCACTTACCTCATTGGGAGAG
 AAGTGTCTTTTGTGTGACCGCATGAAGTGGATTGCATGCAACAACAAAGGCTACTACACGCAGATCT
 CAACGCTGGCGGACACCCAGGAGAAGCTGATGGAATACCTGCACGTGCTCAGCCGCCCCATGGTCA
35 TCAACCACGACACGACATCATCTGGACAGAGGCCCTACATGGACAGCAAGCTCCTCAGCTCGCAGG
 CTCAGAGCCTGACACTGCTCACCCTGTGGCCATGCCAGTCTTCAGCAAGAAGAACGAAACGCCGAT
 CCCATGGCATTTCTCTGGGTGTGGTGGGCTCAGATGTGGCCCTGAGAGAGCTGATGAAGCTGGCGC
 CCCGGTACAAGCTTGGAGTGCACGGATACGCCCTTCTGAACACCAACAATGGGTACATCCTCTCCC
 ATCCCGACCTCCGGCCCCCTGTACAGAGAGGGGAAGAACTAAAACCCAAACCTAACTACAACAGTG
40 TGGATCTCTCCGAAGTGGAGTGGGAAGACCAGGCTGAATCTCTGAGAACAGCCATGATCAATAGGG
 AAACAGGTACTCTCTCGATGGATGTGAAGGTTCCGATGGATAAAGGGAAGCGAGTTCTTTTCTCTGA
 CCAATGACTACTTCTTCACGGACATCAGCGACACCCCTTTCAGTTTGGGGGTGGTGTGTCCCGGG
 GCCACGGAGAATACATCCTTCTGGGGAAACAGTCTGTGGAAGAAGGCCTGCATGACTTGCTTCACC
 CAGACCTGGCCCTGGCCGGTGACTGGATCTACTGCATCACAGATATTGACCCAGACACCGGAAGC
45 TCAGCCAGCTAGAGGCCATGATCCGCTTCTCACCAGGAAGGACCCAGACCTGGAGTGTGACGAGG
 AGCTGGTCCGGGAGGTGCTGTTTGACGCGGTGGTGACAGCCCCATGGAAGCCTACTGGACAGCGC
 TGGCCCTCAACATGTCCGAGGAGTCTGAACACGTGGTGGACATGGCCTTCTGGGACCCCGGGCTG
 GCCTCCTGAGAAGCAGCTTGTTCGTGGGCTCCGAGAAGGTCTCCGACAGGAAGTTCTGACACCTG
 AGGACGAGGCCAGCGTGTTCACCTGGACCGCTTCCCGCTGTGGTACCGCCAGGCCTCAGAGCATC
50 CTGCTGGCAGCTTCGTCTTCAACCTCCGCTGGGCGAGAAGGACCAGAAAGTGCGGGTGAACCCATGG
 TGGTGACGGCAAGCACAGCTGTGGCGGTGACCGTGGACAAGAGGACAGCCATTGCTGCAGCCGCGG
 GCGTCCAAATGAAGCTGGAATTCCTCCAGCGCAAATTCCTGGGCGGCAACGCGGCAGTGCAGCACTG
 TGGATGGGCGGTGCACACAGAGCTGCGAGGACAGTGATCTGGACTGCTTCGTCTATCGACAACAACG
 GGTTCATTCTGATCTCCAAGAGGTCCCGAGAGACGGGAAGATTTCTGGGGGAGGTGGATGGTGTG
55 TCCTGACCCAGCTGCTCAGCATGGGGGTGTTACGCCAAGTGACTATGTATGACTATCAGGCCATGT
 GCAAACCTCGAGTCACCACCACAGTGACAGCCAGCCCCCTGGTCAGCCCAATTTCTGCCTTCTTGA

CGGCGACCAGGTGGCTGCTGCAGGAGCTGGTGCTTGTGAGTGGGGGTAGACACGGGGCTGGTGGAG
GCTGCAATGCGAGGGTGGCTTAGGAGGGTGTCTTGATCAGGAGGCTGCAAGGTCTCCAGGACAACC
CACTTGCTACCAAGACCCCGGGGAAGGAGGGCACAATCCCTGGGCATGGACGCCACCTCTTCCCTG
CATGCTTGCCCCCTGGGAGGGACCTCATTGCTCAACCAGAGCCCTCAAGCAGGGAAGAGGGTGTCT
5 GGAGGAGAGGGGATGGGCCGGGGCTGTGAGGGATACTCCAGCTCCTTGGGAACCCAAGTCGGGAG
GGCTCAGAGGTCTCCGAGATTCACTCCTGTGTCTGACAGGTTCTGCTGGAGTGGAGTGTCTGGGG
CTCCTGGTACGACAGAGGGGCCGAGGGTGAGTGCACGGAGCTGCAGGGCCATGTGCTGAAGAGCAG
TGGCATTTTGGTCCACTAACGTGAGACCATTCCTGTGGGGTGGGTGACAGTGGGGATAGGTGACC
10 CTGAAGCATCGTTGTTCACATCTCACCTGCGTGGCCTTCTCTCATCACATCCCTCAGCTCCTGGCT
CTGTGTGTGACATCATCTTGGGACACCGCCACTCCATGTGCCATCATCACCACCCCATGACATCCT
GCCCTCATGTGCCACCATGTTTTCTGTGCCGTGTCCACCCTGTGCTGGGCTTATGTTCCGGCCAG
CCAAAAGTGTCTTCCATCACTCCCAAAACACAAGAAGCAGGACCCGCTGCAGCCCTGCGACACGG
AGTACCCCGTGTCTGTACAGCCGG: CCATCCGGGAGGCCAACGGGATCGTGGAGTGCAGGGCCC
15 TGCCAGAAGGTATTTGTGGTGCAGCAGATTCCCAACAGTAACCTCCTCCTCCTGGTGACAGACCCC
ACCTGTGACTGCAGCATCTTCCCACAGTGCTGCAGGAGGCGACAGAAGTCAAATATAATGCCTCT
GTCAAATGTGACCGGATGCGCTCCCAAGCTCCGCCGGCGACCACTCCTGCCACGCCCTTCCAT
CCAGAGGAGAATGCCAGGACTGCGGYGGCGCCTCGGACACCTCAGCCTCGCCGCCCTACTCCTG
CTGCCCTGTGTGCTTGGGGCTACTGCCCAACTCCTGCGGTGACACCACCCAGCCTGACCTGTG
20 TTTTGCAAGGTGATCCTTCCAGAGCCATCCCAAAAAGTCAGCACTGACATGGGATGCAGCTAACT
GCAGTTGGGTGCGCCCCCAGGCCAACGCTCCTCTCAATCCTGGGCTGGTGGCCCCCTGGTCCGGAGA
ATGCTGGATGGAACAGGAAACCAATCACCTGGCACCACCTTCAAGATGCTTCATGGTGCCCGGTAC
CATCTGCCCTAGGTCTCAACATGAGCATACTTCTGACCTAACCTTCTGTCTCCTCTTCCGGAAGC
CAGCGTGAGCTCAGCTTGGACCAAGACAAAATAATTAGTTCTTCTCTGTACTCCAGAGTCCAGACC
25 CAGCCAAGAAAGGGTCAGTTGTTTCTGACCCCTTCTGTGCGAGTGGTCTCTGGTAGAACCCAAGGA
CTTCTGGGTACTGAGAAGCAGCAGCAGAATGAGGCCAAATGCAGAGATGAGGCTAAGGCAAGAATA
TGCCCCAACTAAAGCATAGATTCCCCAAAGTGAGGCTCATGGTGGGAGGCCACTCACCTTCTTAGC
TGCTGCTCGAAAAGGTTTGTACTGTGTGGGGTGGGGGTGGGTAAGGGAATGGTCAAGACTGAGA
AAGGAATGAAATCCATTACAGGAAATATCGACAGGGCTACACGTGATGTCCCCAACTGCTGCTATT
30 GAAGAACTTCCCAAACTTCTTTACAAAGCCCTAAAGGAAAGTTGCACTCTATGAAAAGCCAATAG
GCTGAGACATCCAATTGCTGCATGGAAATTGATGTACATTACAGGGGACGGCAAAAATAGCTGTAAA
ATAGTGAAAAAGAGCAGTGGTTGTGCTCTTTCTGGCCAATGATTTACAAAAGAACTACTTGACT
CTGTCCCTGGAGTGAATCCTTAGGGTTGGAACCTGTGGGAACATTCCAACCTGCTAAGCAGGGTC
CACTGGGAGGGAAGCTCTATCTGGGAACTCACCCCCAGCGCACACACATCTCCCCAGGGTCCCAA
35 GGCCCCGCGAGCTTCTCCCCCGACCAACCCCAAGACCTGGATCCCAGGAGACAACAGTCTCCACA
TGAGAGCAACATTAAGGGCAAAGCCATGGAGAAATGTGGGAGAGGCCGGCCTCAAATCTTTCATT
TAACAAACCCCAAGTGATGGGTATGGACAGCATGCAGGGCTTTTGGGGCGCTTCCCCCGCTCCTCC
ATCACCCCTCAGCCTCCACACTTCAAAGTTCAAAGTTCAAAGCTGTTCAAAGTTTCTACCAGCAAATA
GCCCTAACTTGCTCTAGAGTAGGCCAAATGCCAACTCTGTAACACACACTTACATTATCGGTTAC
40 AGAATGTCACTCTTACCATCATGTCTTGCAACAACCCTGTGAGGGCAGTATTAATGCCCCCTTACA
GCAGAAGACACTGCAGCTCGAAGACAGCTTAAGTGGCAGAATAATGTAGAACAGCTAAGGTTTAC
ATGTACCAAATAACATGTTTCAGCTCATTCCATCCTCACAACAGCCCCCTGAAAGTGGGTACTATC
ATTAGTCCCATGTTATAGAACTGCAGCAGAGTTGAAAATTGCCTCCAAATTACCGGAAGAGTGTA
TGAAGATTGAATGTGATGTATTACGTAAACATGCTTGAAACTGCCTGGCATATACTAAACGCTAAA
TAAATACATGCTAACTGCAAAAAAAAAAAAAAAAAAAAAA

45

(2) INFORMATION FOR SEQ ID NO: 17

(i) SEQUENCE CHARACTERISTICS:

50

- (A) LENGTH:
- (B) TYPE:
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

55

- (A) NAME/KEY:
- (B) LOCATION:

(D) OTHER INFORMATION: human variant $\alpha 2\delta$ -D, EDGE screen

(iii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

5 MPATPNFLANPSSSRWIPQMPVAVAFVQKTSALLWLLLLGTSLSPAWGQAKIPLETV
KLWADTFGGDLNTVTKYSGSLLLQKKYKDVESLKEEVDGLELVRKFSEDMENMLRR
KVEAVQNLVEAAEEADLNHEFNESLVFDYYNSVLINERDEKGNFVELGAEFLESNAHFS
10 NLPVNTSISSVQLPTNVYNKDPDILNGVYMSEALNAVFVENFQRDPTLTWQYFGSATGFF
RIYPGIKWTPDENGVTDFDCRNRGWYIQAATSPKDIVILVDVSGSMKGLRMTIAKHTITIL
DTLGENDFVNIIAYNDYVHYIEPCFKGILVQADRDNREHFLLVEELMVKGVGVDQALR
EAFQILKQFQEAQGSCLCNQAJMLISDGAVEDYEPVFEKYNWPDCKVRVFTYLIGREVSF
ADRMKWIACNNKGYTQISTLADTQENVMEYLHVLSRPMVINHDHDIIWTEAYMDSKLL
SSQAQSLTLLTTVAMPVFSKKNETRSHGILLGVVGSVALRELMLKLAPRYKLGVBHGYAFL
15 NTNNGYILSHPDRLPLYREGKKLKPKPNYSVDLSEVEWEDQAESKRVLFTNDYFFTDI
SDTPFSLGVLSRGHGEYILLGNTSVEEGLHDLHPDLALAGDWYICITIDPDHKLSQL
EAMIRFLTRKDPDLECEELVREVLFDVVTAPMEAYWTALALNMSESEHVVDMAFLG
TRAGLLRSSLFVGSEKVS DRKFLTPEDASVFTLDRFPLWYRQASEHPAGSFVFNLRWAE
GPESAGEPMVVTASTAVAVTVDKRTAIAAAAAGVQMKLEFLQRKFWAATROCSTVDGPC
20 TQSCEDSDLD CFVIDNNGFILISKRSRETGRFLGEVDGAVLTQLLSMGVFSQVTMYDYQA
MCKPSSHHSAAQPLVSPISAFLTATRLLQELVLFLEWSVWGSWYDRGAEAKSVFHH
SHKHKKQDPLQPCDTEYPVFVYQPAIREANGIVECGPCQKV FVVQQIPNSNLLLLVTDPTC
DCSIFPPVLQEATEVKYNASVKCDRMRSQKLRRRPSCHAFHPEENAQDCGGASDTSASP
PLLLPVCAWGLLPQLLR

25

(2) INFORMATION FOR SEQ ID NO: 18

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

35 (A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 5' primer for human $\alpha 2\delta$ -D

(iii) MOLECULE TYPE: cDNA

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GCGAGGACAGTGATCTGG

45

(2) INFORMATION FOR SEQ ID NO: 19

(i) SEQUENCE CHARACTERISTICS:

50 (A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 3' primer for human $\alpha 2\delta$ -D

5

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

GGGTCCTCGTTCTTGTTT

10

(2) INFORMATION FOR SEQ ID NO: 20

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

15

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

20

(B) LOCATION:

(D) OTHER INFORMATION: nested primer for human $\alpha 2\delta$ -D

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

25

TCAGCCTCCACACTTCAAAG

(2) INFORMATION FOR SEQ ID NO: 21

(i) SEQUENCE CHARACTERISTICS:

30

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

35

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: primer for human $\alpha 2\delta$ -D

(iii) MOLECULE TYPE: cDNA

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

TCCGCCTGGACGAGGATCC

45

(2) INFORMATION FOR SEQ ID NO: 22

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
5 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
10 (D) OTHER INFORMATION: primer for human $\alpha 2\delta$ -D
 (iii) MOLECULE TYPE: cDNA
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:
GTGTCCAAGATGGTGGTGAT
15
(2) INFORMATION FOR SEQ ID NO: 23
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
20 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
25 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION: primer for human $\alpha 2\delta$ -D (d20)
 (iii) MOLECULE TYPE: cDNA
30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:
ATCTACTGCATCACAGATATTG

(2) INFORMATION FOR SEQ ID NO: 24
35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
40 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION: primer for human $\alpha 2\delta$ -D ($\alpha 2\delta$ D2)
45 (iii) MOLECULE TYPE: cDNA
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

GGTGAGGAAGCGGATCATG

(2) INFORMATION FOR SEQ ID NO: 25

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- 10 (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: Coding Sequence
(B) LOCATION:
(D) OTHER INFORMATION: 5' primer mouse genomic of $\alpha 2\delta$ -B
- 15 (iii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:
TTCAACGAGAAGGCACAGCCT

20 (2) INFORMATION FOR SEQ ID NO: 26

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
25 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: Coding Sequence
- 30 (B) LOCATION:
(D) OTHER INFORMATION: 3' primer mouse genomic of $\alpha 2\delta$ -B
- (iii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:
35 GTTGGCACAGGCCATCCACTG

(2) INFORMATION FOR SEQ ID NO: 27

- 40 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- 45 (ix) FEATURE:
(A) NAME/KEY: Coding Sequence
(B) LOCATION:

(D) OTHER INFORMATION: primer for sequencing mouse genomic,
based on human

(iii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:
AGGCTGTGCCTTCTCGTTGAA

(2) INFORMATION FOR SEQ ID NO: 28

10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

20 (D) OTHER INFORMATION: primer for sequencing mouse genomic,
based on human

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:
GAGCCCCCAAGAAGATCG

25

(2) INFORMATION FOR SEQ ID NO: 29

30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

35 (A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: primer for sequencing mouse genomic,
based on human

(iii) MOLECULE TYPE: cDNA

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:
CGATCTTCTTG GGGGCTC

45 (2) INFORMATION FOR SEQ ID NO: 30

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
5 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
10 (D) OTHER INFORMATION: primer for sequencing mouse genomic,
based on human
 (iii) MOLECULE TYPE: cDNA
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:
15 CACGATGATGACCATGTC

(2) INFORMATION FOR SEQ ID NO: 31

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: cDNA
25 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION: primer for sequencing mouse genomic,
based on mouse
30 (iii) MOLECULE TYPE: cDNA
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:
GGCAAGACCCTACACTGTTG

35 (2) INFORMATION FOR SEQ ID NO: 32

 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
40 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
45 (B) LOCATION:

(D) OTHER INFORMATION: primer for sequencing mouse genomic,
based on mouse

(iii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:
CCTGGTAATAGCGAGTGAC

(2) INFORMATION FOR SEQ ID NO: 33

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

20 (D) OTHER INFORMATION: 5' genomic sequence from 10kb
fragment for mouse $\alpha 2\delta$ -B

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

25 AAGCTTCTCTCTCATCACCAGGAGGAAGACATCATGTACTACGATGCCAAGGCTGACG
CCGAGCTGGTAAGTGTCCCCACCTTTGCCGTAGAGGATGGGGAGCAGCCAGAGCCAC
ACCTTGTTCTTCTGGGCCACAACAGTCTCAGCTGTAAAGTGGGTGTTAGGGATCCATG
CTCACCTTCTGAACTCAACCATTCGTGTCGTGCTTGGTCAGCCTCTCCTTGCCACA
GCTCCCTAGAGATCCTTGACCCTCCAGGGCGTGTCTTCATCACCATTATAGGCTAAGC
30 TCCCCCTGCACCATGTGGAGCAAGCAGGGTGGTAGAGTGTGGATATCAGGGTGGTTC
CATCCCAGTATGAGGGGCTCTCTGGGCTCCATGGGAGTAGAGAGGAGAAAGAAATGG
ACTCCAGGACCTCCTGGGGTAGGTACATGGGAGTGAGACATGGTGACATCTAAGCCC
TGCCAGGACAGTAGAGGCTCCTTTCTTGTGATTTGGGGAACTTGCATCAAGCTAT
GTAGAAGAACCCATGG

35 (2) INFORMATION FOR SEQ ID NO: 34

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

40 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

45 (B) LOCATION:

(D) OTHER INFORMATION: 3' genomic sequence from 10kb
fragment for mouse $\alpha 2\delta$ -B

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

5 CAGGTGGCCTGTGGCTGGGCCCTTCTCTGAACACTCACAGTGGAGACAGGGCTGGCC
ACAGNAGACCCCATCCTTCTCTCCCTTCAGGGGCTGGGGTTGGTGGTAACAGGAACTT
CTCCCTGTTTTCAACCTGACACAGGATGGCCCTGGGGAAAAGAAGGTGAGTTGCCAG
TGGGTTATCTGGGGAGGAGTTGGCATGCCTGGAGCAGGTCTGGGGATGGAGGAGGGT
TAGGGCATGCTACAGATTGGCAAAGCAGCTCTCCGTATCAGCAGCTTAGCCCTTAGG
10 CCTGGGCCAGGGGGTTCTACTATGGAGTTGACTCATTATAGCATACCTTCCCATTCCCTT
TGTGTCCAGAACCAGTTAATCCTGGGTGTCATGGGCATCGATGTGGCCTTGAATGACA
TCAAAGGCTGACTCCCAACTACACAGTAAGTGTCCACCTGCCCCTCTGCCCTGGTTT
GCTGTCCATAGTGACACAAGCCAGACTCAGCAGGGGAGACATGGGGACTGAAAGACC
GTCACAGAAAGACTTCCCAAAGGGTTTGTCTGAAGCTGTGGACAGCAAGC

15 (2) INFORMATION FOR SEQ ID NO: 35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

20 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

25 (B) LOCATION:

(D) OTHER INFORMATION: 1.8 kb mouse genomic sequence for

mouse $\alpha 2\delta$ -B

(iii) MOLECULE TYPE: cDNA

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

GCTTTCTTGTGGCTGCGGGCCTTGGAGTGCATGCTGAGTGGGTGAGCTCCCTGGGGGGC
CGGCTGCAGGCTCCAGGCAAGCATGCTGGATGGGGGCCAGCTCACAGCTCCCTGCC
ACCCAGGCGGCCCTTCTCCACAGGCCACAAACCACATCAGCCCTGCTTGCTCACCAG
35 GCCTGGATGAGGGGTAGGCTGAGATATTTCTTTGATGATTTAGAGGAGGGAGAGCAA
GAAAATCTCCCTGGAAGAGCTGGTGTGGCCCCACATGAGATCCTGGGAAATCAAAGA
AAGCCTGGGCAGGCAGAAAGCAGGGGAGGCCATGGAGATGGGTTTAGCAGGGGGCG
ACCCTGAACCTCCCAACCCAGCCTTCTGCCCTGCCCCTCAGCTACCGTCATCCTCAAT
GAGCTTAACTGGACAGAGGCCCTGGAGAACGTCCTTCATTGAGAACCGTAGGCAAGAC
40 CCTACACTGTTGTGGCAAGTCTTTGGCAGTGCCACGGGAGTCACTCGCTATTACCCAG
GTAGGCACCACTGTCTCCCTGGCCCATCCAGCACCCGTCCTTGCTCCATCTCCAAGCCTA
CCCATTCTGAGGTCCATGGGGTACAATGAACCAGGTCAATCCCCATCACTCCCGCCTG
CTCCAGTCAGACCCTTCTGCCGGGCCGGGCCCTTCACCCCTCTTTCCACAGCCACAC
CATGGCGAGCCCCAAGAAGATTGACCTGTACGATGTCAGAAGACGACCCTGGTGAG
TGAGCAAGGGGGGTGGAGGCGAGACACCCCTCAACTCCCCATCTCTCGTGCCCGCTC
45 CCTCCCTCCCAATATCCAGACCTCCGAGCAGGGCGCAGCCAGCTCTATCCAATTTTC
ATTTACACATCGCTGCCACTGGAATGGATCCCATCGCCAGGCAAGCCGCCAGC
TGCTCTGCCCCACGCGTGTCTGCTCACTACCCAGCCCCCCCCACCCACTCAGAACT
GAGAGCAGACCAGGGAAGGTGCTTCCAGGGGTAGCTAGAGCCTCCGTGAGGTGAGCC
GGCCCCACTACTCATTGATCCCTGGACACCCCGACCCTCTGCTCTGCTCTCTCACA
50 CTACTCCATGATCTTCCCTCCCTCCTCCATTACACAGCCAGACTCTCTGGAGTCTCTCT
AGGACAGAGGACACAAGCCACTAAAGCCTTCTGTCCCGTGGATCACCTGCCCCTTCC
CCCTCACCTCTTGTCTTACTTAATGAGGGAACCAGATCACTCACGTACAAGAAAAAAA
AAACTGTCTTTTGTATTGAGCATGGTCTCCCAAGTGCCAGACCTATTCCAACCCCTG

5 TAGTGCGTGGTCAGTAGAAACACAGGAATCAAGTGGGTGGAAGAAGGAAGACCCCGC
AGGTCCCGGAGGTGCCGTCCTTAAGTGAAGTCTTCTCACTGGCAGGTATATACAGGGGG
CCTCATCACCCAAGGACATGGTCATCATTGTGGATGTGTGAGTGAGCCTTGTAGGCTG
GTGGGATGGGCTAGGACTGGAAGTCTGCTTCTGGGCACCTTATGAGGGAAGGGCGGG
10 AAAACCCTGAGAGCCCACATGCATGCGCCCCCTTCCGTGCCTGGTTTCCAGGAGTGGG
AGCGTGAGCGGCCTGACTCTGAAGCTGATGAAGACGTCCTGTGAGATGCTAGAC
ACGCTCTCTGATGATGACTATGTGAACGTGGCCTCAGTGAGTGGCAAGGTGGCAGGC
AGGCTGGGTACCACTCACCCCCATCAACCTGCTCCCATGACAACCATCAGCCCTGTA
CAACAGCTGCACACTGTGTGGCCAGCCTGAAGCCACTCACCACCCCCCACTGTCCCCA
CAG

(2) INFORMATION FOR SEQ ID NO: 36

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
20 (ix) FEATURE:
(A) NAME/KEY: Coding Sequence
(B) LOCATION:
(D) OTHER INFORMATION: 5' primers to amplify rat sequences for
 $\alpha 2\delta$ -C, PCR 1

25 (iii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:
GACAGGACCAACAAGGAGCAC

30 (2) INFORMATION FOR SEQ ID NO: 37

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
35 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: Coding Sequence
40 (B) LOCATION:
(D) OTHER INFORMATION: 3' primers to amplify rat sequences for
 $\alpha 2\delta$ -C, PCR 1

(iii) MOLECULE TYPE: cDNA
45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:
GCCAACCACACCCAGAAGAAT

(2) INFORMATION FOR SEQ ID NO: 38

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 5' primers to amplify rat sequences for

 α 2 δ -C, PCR 5

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

AACGCACCATCAAGGAGACCA

(2) INFORMATION FOR SEQ ID NO: 39

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: 3' primers to amplify rat sequences for

 α 2 δ -C, PCR 5

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

AGGGGCAGCAGCAGCAAG

(2) INFORMATION FOR SEQ ID NO: 40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: PCR1 product, rat $\alpha 2\delta$ -C

(iii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

TTCAGGGAGCATTGGACAACTTTTGGCCAAAGGGATTGGAATGCTCGATATTGCGCTGAACGAG
GCCTTCAATGTACTGAGCGATTTCAACCACACCGGACAAGGAAGCATTTCAGCCAGGCCATTATG
CTCATAACCGATGGGGCARTGGACACCTACGAYACCATCTTTGCAAAGTACAATTGGCCAGAGCGA
AAGGTTCTGAATCTTCACTTACCTCATTGGACGAGAGGCTGCTTTGCGAGACAATCTCAAGTGGATR
10 GCTTGTGCTAACAAAGGATTTTCACCCAGATCTCCACCTTGGCTGATGTGCAGGAAAATGTCATG
GAATACCTCCATGTACTCAGTCGACCCAAAGTCATCGACCAGGAACATGATGTGGTGTGGACCGAA
GCGTACATCGACAGCACTCTCCCTCAGGCTCAAAAGCTTGCTGATGATCAGGGCCTCGTCTTGATG
ACCACAGTGGCCATGCCTGTGTTTAGTAAGCAGAACGAACTAGGTCAAAGGGC

15

(2) INFORMATION FOR SEQ ID NO: 41

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

20

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

25

(A) NAME/KEY: Coding Sequence

(B) LOCATION:

(D) OTHER INFORMATION: PCR5 product, rat $\alpha 2\delta$ -C

(iii) MOLECULE TYPE: cDNA

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

CAGGGAACATTGCTTGTGAAGAYTGCTCCAAGTCCTTTGTCATCCAGCAAATCCCAAGTAGCAATC
TGTTTCATGGYGGTGGTGGACAGTAGCTGTCTGTGAGTCTGTGGCTCCTATCACCATGGCACCCA
TTGAAATCAGGTATAATGAATCCCTTAAGTGTGAACGGTTAAAGGCTCAGAAGATCAGACGACGTC
CGGAATCCTGCCACGGCTTCCATCCTGAGGAGAATGCGAGAGAGTGTGGGGGTGCATCAAGTCTCC
35 AGGCCCAGGT

(2) INFORMATION FOR SEQ ID NO: 42

(i) SEQUENCE CHARACTERISTICS:

40

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

45

(ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(D) OTHER INFORMATION: Human $\alpha 2\delta$ -D variant

(iii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

MPATPNFLANPSSSRWIPLOPMPVAWAFVQKTSALLWLLLLGTSLSPAWGQAKIPLETV
 5 K LWADTFGGDL YNTVTKYSGSLLLOKKYKD VESSLKIEEVDGLELVRKFSEDMENMLRR
 KVEAVQNLVEAAEEADLNHEFNESLVFDYYNSVLINERDEKGNFVELGAEFLESNAHFS
 NLPVNTSISSVQLPTNVYNKDPDILNGVYMSEALNAVVENFORDPTLTWQYFGSATGFF
 RIYPGIKWTPDENG VITFD CRNRGWYIQAATSPKDIVILVDVSGSMKGLRMTIAKHITITI
 10 LDTLGENDFXNIIAYNDYVHYIEPCFKGILVQADRDNREHFKLLVEELMVKGVGVDQAL
 REAFQILKQFQEAQKQSLCNQAIMLISDGAVEDYEPVFEKYNWPDCKVRVFTYLIGREVSF
 ADRMKWIACNNKGYTQISTLADTQENVMEYLHVLSRPMVINHDHDIIWTEAYMDSKLL
 SSQAQSLTLLTTVAMPVFSKKNETRSHGILLGVVGS DVALRELMKLAPRYKLG VHG YAFL
 NTNNGYILSHPDRLPLYREGKKLKPKNYNSVDLSEVEWEDQAESLRTAMINRETGTLSM
 DVKVPMDKGKRVLFLTNDYFFTDISDTPFSLGVVLSRGHGEYILLGNTSVEEGLHDLHPD
 15 LALAGDWIYCITDIDPDHRKLSQLEAMIRFLTRKDPDLECEELVREVLFD AVVTAPMEA
 YWTALALNMSESEHVVDMAFLGTRAGLLRSSLVGSEKVS DRKFLTPED EASVFTLDRF
 PLWYRQASEHPAGSFVFNLRWAEGPESAGEPMVVTASTAVAVTVDKRTAIAAAAGVQM
 KLEFLQRKFWAATRQCSTVDGPCTQSCEDSDLD CFVIDNNGFILISKRSRETGRFLGEVDG
 AVL TQLLSMGVFSQVTMYDYQAMCKPSSHHSAAQPLVSPISAFLTATRWLLQELVLVS
 20 GGRHGAGGGGCMRGWLRVSLIRRLQGLQDNPLATKTPGKEGTIPGHGRHLPACPLGG
 TSLLNQSPQAGKRVS WRRGDGP AVRDT P APWEPKSGGLRGLRDSVLCLTGSCWSGVSG
 APGTTEGPRVSARSCRAMC

(2) INFORMATION FOR SEQ ID NO: 43:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 30 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION: >1907 α 28-C, potent. soluble form
 35 (iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

TACTATAGGGCGGCCGCGAATTCGGCACGAGGCGGCGGAGCGGAGCAGGCAGCCCCGCGCGCTC
 40 GCCCACC GCCCGCTCCGCGCAGCTCCCCGCGCGCTCTCGTCGCCGCCGCGAGCGGGCGCTCGGA
 GGGAGCCCAGCATGGCCGGGCGGGCTCGCCGCGCGCGCTCCCGGGGGGCTCGGCGCTTCTCG
 CTGCCGCGCTTCTCTACGCCGCGCTGGGGGACGTGGTGCGCTCGGAGCAGCAGATACCGCTCTCCG
 TGGTGAAGCTCTGGGCCTCGGCTTTTGGTGGGAGATAAAATCCATTGCTGCTAAGTACTCCGGTT
 CCCAGCTTCTGCAAAAGAAATACAAAGAGTATGAGAAAGACGTTGCCATAGAAGAAATTGATGGCC
 45 TCCAAGTGTAAAGAAGCTGGCAAAGAACATGGAAGAGATGTTTCAAGAAGCTCTGAGGCCGTCA
 GCGCTCTGGTGGAGGCTGCAGAAGAAGCACACCTGAAACATGAATTTGATGCAGACTTACAGTATG
 AATACTTCAATGCTGTGCTGATAAATGAAAGGGACAAAGACGGGAATTTTTTGGAGCTGGGAAAGG
 AATTCATCTTAGCCCCAATGACCATTTTAATAATTTGCCTGTGAACATCAGTCTAAGTGACGTC
 AAGTACCAACGAACATGTACAACAAAGACCTGCAATTGTCAATGGGGTTTATTGGTCTGAATCTC
 50 TAAACAAAGTTTTTGTAGATAACTTTGACCGTGACCCATCTCTCATATGGCAGTACTTTGGAAGTG
 CAAAGGGCTTTTTTAGGAGTATCCGGGGATTAAATGGGAACAGATGAGAAATGGAGTCATTGGCT
 TCGACTGCAGGAACCGAAAATGGTACATCCAGGCAGCAACTTCTCGAAAGACGTGGTCATTTTAG
 TTGACGTCAGTGGCAGCATGAAAGGACTCCGTCTGACTATCGCGAAGCAAACAGTCTCATCCATTT
 TGGATACACTTGGGGATGATGACTTCTTCAACATAATTGCTTATAATGAGGAGCTTCACTATGTGG
 AACCTTGCTGAATGGAACCTTGGTGCAAGCCGACAGGACAAACAAAGAGCACTTCAGGGAGCATC

5 TGGACAAACTTTTCGCCAAAGGAATTGGAATGTTGGATATAGYTCTGAATGAGGCCTTCAACATTC
TGAGTGATTTC AACCCACACGGGACAAGGAAGTATCTGCAGTCAGGCCATCATGCTCATAACTGATG
GGGCGGTGGACACCTATGATACAATCTTTGCAAAATACAATTGGCCAGATCGAAAGGTTTCGCATCT
TCACATACCTCATTGGACGAGAGGCTGCGTTTGACAGACAATCTAAAGTGGATGGCCTGTGCCAACA
10 AAGGATTTTTTACCCAGATCTCCACCTTGGCTGATGTGCAGGAGAATGTGATGGAATACCTTCACG
TGCTTAGCCGGCCCAAAGTCATCGACCAGGAGCATGATGTGGTGTGGACCGAAGCTTACATTGACA
GCACTCTGACTGATGATCAGGGCCCCGTCCTGATGACCACTGTAGCCATGCCTGTGTTTAGTAAAGC
AGAACGAAACCAGATCGAAGGGCATTCTTCTGGGAGTGGTGGCACAGATGTCCAGTGAAAGAAC
TTCTGAAGACCATCCCCAAATACAAGTTAGGGATTACGGTTATGCCTTTGCAATCACAAATAATG
15 GATATATCCTGACGCATCCGGAACCTCAGGCTGCTGTACGAAGAAGGAAAAAGCGAAGGAAACCTA
ACTATAGTAGCGTTGACCTCTCTGAGGTGGAGTGGGAAGACCGAGATGACGTGTTGAGAAATGCTA
TGGTGAATCGAAAGACGGGGAGTTTTCCATGGAGGTGAAGAAGACAGTGGACAAAGGGGTACATT
TTTCTCAAACATTTTTGCTGCTTAATTTAAACAAACCACTGTGAAAAATTAGCTTTGAAAGCTAT
ATCTGGAATAAATATCTTTCGCTGAAGG

(2) INFORMATION FOR SEQ ID NO: 44:

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
25 (ix) FEATURE:
(A) NAME/KEY: Coding Sequence
(B) LOCATION:
(D) OTHER INFORMATION: $\alpha 2\delta$ -C, (2686-2745, 2892-3001)
(iii) MOLECULE TYPE: cDNA
30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

35 TACTATAGGGCGGCCGCGAATTCGGCAGCAGGCGGCGGAGCGGAGCAGGCAGCCCCGCGCGCTC
GCCCCACGCCCCGCTCCGCGCAGCTCCCCGCGGCGGCTCTCGTCGCCGCCGCGAGCGGGCGCGCTCGGA
GGGAGCCCAGCATGGCCGGGCGGGCTCGCCGCGCCGCGCGTCCCGGGGGGCCCTCGGCGCTTCTCG
CTGCCGCGCTTCTCTACGCCGCGCTGGGGGACGTGGTGGCTCGGAGCAGCAGATACCGCTCTCCG
40 TGGTGAAGCTCTGGGCCTCGGCTTTTGGTGGGGAGATAAAATCCATTGCTGCTAAGTACTCCGGTT
CCCAGCTTCTGCAAAAGAAATACAAGAGTATGAGAAAGACGTTGCCATAGAAGAAATTGATGGCC
TCCAACCTGGTAAAGAAGCTGGCAAAGAACATGGAAGAGATGTTTACAAGAAGTCTGAGGCCGTCA
GGCGTCTGGTGGAGGCTGCAGAAGAAGCACACCTGAAACATGAATTTGATGCAGACTTACAGTATG
45 AATACTTCAATGCTGTGCTGATAAATGAAAGGGACAAAGACGGGAATTTTTTGGAGCTGGGAAAGG
AATTCATCTTAGCCCCAAATGACCATTTAATAATTTGCCTGTGAACATCAGTCTAAGTGACGTCC
AAGTACCAACGAACATGTACAACAAAGACCCTGCAATTGTCAATGGGGTTTATTGGTCTGAATCTC
TAAACAAAGTTTTTGTAGATAACTTTGACCGTGACCCATCTCTCATATGGCAGTACTTTGGAAGTG
CAAAGGGCTTTTTTAGGCAGTATCCGGGGATTAAATGGGAACCAGATGAGAATGGAGTCATTGCCT
50 TCGACTGCAGGAACCGAAAATGGTACATCCAGGCAGCAACTTCTCCGAAAGACGTGGTCAATTTAG
TTGACGTGAGTGGCAGCATGAAAGGACTCCGTCTGACTATCGCGAAGCAAACAGTCTCATCCATTT
TGATACACTTGGGGATGATGACTTCTTCAACATAATTGCTTATAATGAGGAGCTTCACTATGTGG
AACCTTGCCTGAATGGAACCTTTGGTGCAAGCCGACAGGACAAACAAAGAGCACTTCAGGGAGCATC
TGGACGAACTTTTCGCCAAAGGAATTGGAATGTTGGATATAGCTCTGAATGAGGCCTTCAACATTC
TGAGTGATTTTCAACCACACGGGACAGGAAGTATCTGCAGTCAGGCCATCATGCTCATAACTGATG
GGGCGGTGGACACCTATGATACAATCTTTGCAAAATACAATTGGCCAGATCGAAAGGTTTCGCATCT
TCACATACCTCATTGGACGAGAGGCTGCGTTTGACAGACAATCTAAAGTGGATGGCCTGTGCCAACA
AAGGATTTTTTACCCAGATCTCCACCTTGGCTGATGTGCAGGAGAATGTGATGGAATACCTTCACG
TGCTTAGCCGGCCCAAAGTCATCGACCAGGAGCATGATGTGGTGTGGACCGAAGCTTACATTGACA

5 GCACTCTGACTGATGATCAGGGCCCCGTCCTGATGACCACTGTAGCCATGCCTGTGTTTAGTAAGC
 AGAACGAAACCAGATCGAAGGGCATTCTCTGGGAGTGTTGGCACAGATGTCCAGTGAAGAAGC
 TTCTGAAGACCATCCCCAAATACAAGTTAGGGATTACGGTTATGCCTTTGCAATCACAAATAATG
 10 GRTATATCCTGACGCATCCGGAACCTCAGGCTGCTGTACGAAGAAGGAAAAAGCGAAGGAAACCTA
 ACTATAGTAGCGTTGACCTCTCTGAGGTGGAGTGGGAAGACCGAGATGACGTGTTGAGAAATGCTA
 TGGTGAATCGAAAGACGGGGAAGTTTTCCATGGAGGTGAAGAAGACAGTGGACAAAGGGAAACGGG
 TTTTGGTGATGACAAATGACTACTATTATACAGACATCAAGGGTACTCCTTTCAGTTTAGGTGTGG
 CGCTTTCCAGAGGTCATGGGAAATATTTCTTCCGAGGGAATGTAACCATCGAAGAAGGCCTGCATG
 15 ACTTAGAACATCCCGATGTGTCTTGGCAGATGAATGGTCTACTGCAACACTGACCTACACCCTG
 AGCACCGCCATCTGTCTCAGTTAGAAGCGATTAAAGCTCTACCTAAAAGGCAAGAACCTCTGCTCC
 AGTGTGATAAAGAATTGATCCAAGAAGTCCTTTTTGACGCGGTGGTGAAGTGCCTTGAAGCGT
 ATTGGACAGCCTGGCCCTCAACAAATCTGAAAATTCTGACAAGGGCGTGGAGGTTGCCTTCCTCG
 GCACTCGCACGGGCCTCTCCAGAATCAACCTGTTTGTGCGGGCTGAGCAGCTCACCATCAGGACT
 TCCTGAAAGCTGGCGACAAGGAGAACATTTTAAACGCAGACCATTTCCCTCTCTGGTACCGAAGAG
 20 CCGCTGAGCAGATTCCAGGGAGCTTCGTCTACTCGATCCCATTCAGCACTGGACCAGTCAATAAAA
 GCAATGTGGTGACAGCAAGTACATCCATCCAGCTCCTGGATGAACGGAAATCTCCTGTGAGTGCAG
 CTGTAGGCATTGAGTGAACCTTGAATTTTTCCAAAGGAAGTCTGGACTGCCAGCAGACAGTGTG
 CTTCCCTGGATGGCAAATGCTCCATCAGCTGTGATGATGAGACTGGAGACTTTTTTGGTGAGATCG
 AGGGAGCTGTGATGAACAAATTGCTAACAAATGGGCTCCTTTAAAAGAATTACCCTTTATGACTACC
 25 AAGCCATGTGTAGAGCCAACAAGGAAGCAGCGATGGCGCCCATGGCCTCCTGGATCCCAGAAATT
 GAAACAGACCCTGGAGCCTTGTGATACTGAATATCCAGCATTCGTCTCTGAGCGCACCATCAAGGA
 GACTACAGGGAATATTGCTTGTGAAGACTGCTCCAAGTCCTTTGTCATCCAGCAAATCCCAAGCAG
 CAACCTGTTTCATGGTGGTGGTGGACAGCAACTGCCTCTGTGAATCTGTGGCCCCCATCACCATGGC
 ACCCATTTGAAATCAGGTATAATGAATCCCTTAAGTGTGAACGTCTAAAGGCCCAGAAGATCAGAAG
 30 GCGCCCAGAATCTTGTGATGGCTTCCATCCTGAGGAGAATGCAAGGGAGTGTGGGGGTGCGCCGAG
 TCTCCAAGCCAGACAGTCCCTCCTTCTGCTCCTCTGCTTTTGATGCTCTTCTCAAGGTGACACTG
 ACTGAGATGTTCTCTTACTGACTGAGATGTTCTCTTGGCATGCTAAATCATGGATAAACTGTGAAC
 CAAAATATGGTGCAACATACGAGACATGAATATAGTCCAACCATCAGCATCTCATCATGATTTTAA
 ACTGTGCGTGATATAAACTCTTAAAGATATGTTGACAAAAAGTTATCTATCATCTTTTTTACTTTGC
 35 CAGTCATGCAAATGTGAGTTTGCCACATGATAATCACCCTTCATCAGAAATGGGACCGCAAGTGGT
 AGGCAGTGTCCCTTCTGCTTGAACCTATTGAAACCAATTTAAAACCTGTGTACTTTTTTAAATAAAG
 TATATTTAAATCATAAAAAAAAAAAAAAAAAAAAAA

35 (2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

40 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

45 (B) LOCATION:

(D) OTHER INFORMATION: adapter primer

(iii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

50 CCATCCTAATACGACTCACTATAGGGC

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
5 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
10 (D) OTHER INFORMATION: adapter primer
 (iii) MOLECULE TYPE: cDNA
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:
15 ACTCACTATAGGGCTCGAGCGGC

(2) INFORMATION FOR SEQ ID NO: 47:

 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
20 (B) TYPE:
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: cDNA
 (ix) FEATURE:
25 (A) NAME/KEY: Coding Sequence
 (B) LOCATION:
 (D) OTHER INFORMATION: probe for Northern blot
 (iii) MOLECULE TYPE: cDNA

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:
CTGTGAGTGCAGCTGTAGGCATTGAGATGAACTTTTCCAAAGGAAGTTCTGGACTGCCA
GCAGACAGTGTGCTTCCCTGGATGGCAAATGCTCCATCAGCTGTGATGATGAGACTGGAGACTTTT
TTGGTGAGATCGAGGGAGCTGTGATGAACAAATTGCTAACAATGGGCTCCTTTAAAGAATTACCC
TTTATGACTACCAAGCCATGTGTAGAGCCAAAGGAAAGCAGCGATGGCGCCCATGGCCTCCTGG
35 ATCCCAGAAATTGAAACAGACCCTGGAGCCTTGTGATACTGAATATCCAGCATTCGTCTCTGAGCG
CACCATCAAGGAGACTACAGGGAATATTGCTTGTGAAGACTGCTCCAAGTCCTTTGTCATCCAGCA
AATCCCAAGCAGCAACCTGTTGATGGTGGTGGACAGCAACTGCCTCTGTGAATCTGTGGCCCC
CATCACCATGGCACCATTGAAATCAGGTATAATGAATCCCTTAAGTGTGAACGTCTAAAGGCCCA
GAAGATCAGAAGGCGCCAGAAATCTTGTCATGGCTTCCATCCTGAGGAGAATGCAAGGGAGTGTGG
40 GGGTGCGCCGAGTCTCCAAGCCAGACAGTCTCCTTCTGCTCCCTCTGCTTTTGATGCTCTTCTC
AAGGTGACACTGACTGAGATGTTCTTTACTGACTGAGATGTTCTCTTGGCATGCTAAATCATGGA
TAACTGTGAACCAAAATATGGTGCAACATACGAGACATGAATATAGTCCAACCATCAGCATCTCA
TCATGATTTTAACTGTGCGTGATATAAACTCTTAAAGATATGTTGACAAAAAGTTATCTATCATC
TTTCTACTTTGCCAGTCATGCAAATGTGAGTTGCCACATGATAATCACCCCTTCATCAGAAATGGG
45 ACCGCAAGTGTAGGCAGTGTCCCTTCTGCTTGAAACCTATTGAAACCAATTTAAACTGTGTACT
TTTAAATAAAGTATATTAAATCATAAAAAAAAAAAAAAAAAAAAAA

50 (2) INFORMATION FOR SEQ ID NO: 48:

 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH:
 (B) TYPE:
 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
5 (A) NAME/KEY: Coding Sequence
(B) LOCATION:
(D) OTHER INFORMATION: Edge 5' primer
(iii) MOLECULE TYPE: cDNA

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:
CTAGAGGCCATGATCCGCTTCCTCAC

(2) INFORMATION FOR SEQ ID NO: 49:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH:
(B) TYPE:
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
20 (ix) FEATURE:
(A) NAME/KEY: Coding Sequence
(B) LOCATION:
(D) OTHER INFORMATION: Edge 3' primer
(iii) MOLECULE TYPE: cDNA
25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:
GCCCACGAACAAGCTGCTTC

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/705, 14/47, 16/18, 16/28, C12Q 1/68, A61K 38/17, G01N 33/68, A61K 48/00		A3	(11) International Publication Number: WO 00/20450 (43) International Publication Date: 13 April 2000 (13.04.00)
(21) International Application Number: PCT/US99/23519 (22) International Filing Date: 7 October 1999 (07.10.99) (30) Priority Data: 60/103,322 7 October 1998 (07.10.98) US 60/106,473 30 October 1998 (30.10.98) US 60/114,088 29 December 1998 (29.12.98) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): JOHNS, Margaret, Ann [US/US]; 2800 Deake Avenue, Ann Arbor, MI 48108 (US). MOLDOVER, Brian [US/US]; 4893 S. Ridgeside Circle, Ann Arbor, MI 48105 (US). OFFORD, James, David [US/US]; 3388 Alan Mark Drive, Ann Arbor, MI 48105 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.			(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 23 November 2000 (23.11.00)
(54) Title: CALCIUM CHANNEL ALPHA-2/DELTA GENE			
(57) Abstract The present invention relates to three novel genes and polypeptides derived therefrom encoding " $\alpha 2\delta$ -C" and/or " $\alpha 2\delta$ -D" proteins which exist as a subunit in many calcium channels. The invention also describes methods for using the novel gene and polypeptides in the detection of genetic deletions of the gene, subcellular localization of the polypeptide, binding assays in connection with chemical databases, gene therapy.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/23519

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/705 C07K14/47 C07K16/18 C07K16/28
C12Q1/68 A61K38/17 G01N33/68 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, STRAND, MEDLINE, BIOSIS, SCISEARCH, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! AC AA190607, 21 January 1997 (1997-01-21) HILLIER, L. ET AL.: "zq44e03.r1 Stratagene hNT neuron, Homosapiens cDNA clone IMAGE: 632572 5' similar to TR:G179762 G179762 Calcium Channel Alpha-2B subunit; mRNA sequence" XP002136760 see the whole document: 97,6% identity in 413bp overlap with SEQ ID No. 3; 96,8% identity in 340bp overlap with SEQ ID No. 43; 97,6% identity in 413bp overlap with SEQ ID No. 44</p> <p style="text-align: center;">--- -/-</p>	1, 2, 22, 23



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

21 July 2000

Date of mailing of the international search report

24.08.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alt, G

INTERNATIONAL SEARCH REPORT

Inter nal Application No

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! AC Z44942, 6 November 1994 (1994-11-06) AUFFRAY, C. ET AL.: "Homo sapiens partial cDNA sequence; clone c-2dd03" XP002136761 see the whole document: 99,7% identity in 340 bp overlap with SEQ ID No. 3; 100% identity in 17bp overlap with SEQ ID No. 11</p>	1,2,22, 23
X	<p>DATABASE EMBL 'Online! AC R20288, 23 April 1995 (1995-04-23) HILLIER, L. ET AL.: "yg20f03.r1 Soares infant brain INIB Homo sapiens cDNA clone IMAGE:32708 5', mRNA sequence" XP002136762 see the whole document: 97,6% identity in 340 bp overlap with SEQ ID No. 3</p>	1,2
X	<p>DATABASE EMBL 'Online! AC AA459684, 13 June 1997 (1997-06-13) HILLIER, L. ET AL.: "zx49d08.s1 Soares testis NHT Homo sapiens cDNA clone 759567 3' EST" XP002136763 see whole document: 100% identity in 304bp overlap with SEQ ID No. 3</p>	1,2
X	<p>WO 95 04822 A (SALK INST BIOTECH IND) 16 February 1995 (1995-02-16) see SEQ ID No. 31: 34,4% identity in 540 aa overlap with SEQ ID No. 5; 29,1% identity in 1122aa overlap with SEQ ID No. 6;</p>	8
X	<p>DATABASE EMBL 'Online! ACAC005343, 4 August 1998 (1998-08-04) MUZNY, D. ET AL.: "Homo sapiens chromosome 12p13.3 BAC RPCI 11-21K20 (Roswell Park Cnacer Institute Human BAC Library) complete sequence" XP002143146 see the whole document: 98,5% identity in 1847 bp overlap with SEQ ID No. 4, 15, 16;</p>	1,2,22, 23
X	<p>DATABASE EMBL 'Online! AC AA719773, 7 January 1998 (1998-01-07) HILLIER, L. ET AL.: "zh38g01.s1 Soares pineal gland N3HPG Homo sapiens cDNA clone 414384 3'" XP002143147 see the whole document: 98,4% identity in 436 bp overlap with SEQ ID NO. 4</p>	1,2,22, 23
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! AC AA001473, 20 July 1996 (1996-07-20) HILLIER, L. ET AL.: "ze45d04.r1 Soares retina N2b4Hr Homo sapiens cDNA clone 361927 5'" XP002143148 see the whole document: 97,8% identity in 489bp overlap with SEQ ID NO. 4, 15, 16</p>	1,2,22, 23
X	<p>WO 98 11131 A (CHEN AI RU SUN ;FRANCO RODRIGO (US); AMERICAN HOME PROD (US); SHUE) 19 March 1998 (1998-03-19) see SEQ ID NO.4: 29,0% identity in 1129aa overlap with SEQ ID No. 6</p>	8
X	<p>DATABASE EMBL 'Online! AC Z75742, 9 July 1996 (1996-07-09) WILKINSON; J.: "Human DNA sequence from cosmid LUCA10 on chromosome 3p21.3 contains ESTs" XP002143149 see the whole document: 82,8% identity in 87bp overlap with SEQ ID No. 33</p>	23
A	<p>DATABASE EMBL 'Online! AC AB011130, 10 April 1998 (1998-04-10) OHARA, O. ET AL.: "Homo sapiens mRNA for KIAA0558 protein, partial cds." XP002143150 see the whole document; 100% identity in 1145aa overlap with SEQ ID No. 2</p>	22-26,34
Y	<p>GEE N S ET AL: "THE NOVEL ANTICONVULSANT DRUG, GABAPENTIN (NEURONTIN), BINDS TO THEALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL" JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 271, no. 10, 8 March 1996 (1996-03-08), pages 5768-5776, XP002022221 ISSN: 0021-9258 cited in the application see the whole document</p>	34

-/-

INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BROWN J P ET AL: "CLONING AND DELETION MUTAGENESIS OF THE ALPHA 2 DELTA CALCIUM CHANNEL SUBUNIT FROM PORCINE CEREBRAL CORTEX" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 39, 1998, pages 25458-25465, XP000887190 ISSN: 0021-9258 see the paragraph bridging pages 25461-25462	34
P, X	KLUGBAUER, N. ET AL.: "Molecular diversity of the calcium channel alpha 2 delta subunit" NEUROSCIENCE, vol. 19, no. 2, 15 January 1999 (1999-01-15), pages 684-691, XP000886459 see Figure 1; 89,4% identity in 1902bp overlap with SEQ ID 3; 94,0% identity in 251bp overlap with SEQ ID No. 14; 94,8% identity in 561 bp overlap with SEQ ID NO. 40; 96,0% identity in 273bp overl overlap with SEQ ID No. 41; 88,0% identity in 1494bp of SEQ ID NO. 43; 88,1% identity in 1494bp overlap with SEQ ID NO. 44; 57,1% identity in 2962bp overlap with SEQ ID No. 4; 65,6% identity in 1454bp overlap with SEQ ID NO. 15; 65,6% identity in 1454bp overlap with SEQ ID No. 16;	1,2,4, 6-10,22, 23
E	WO 00 12711 A (INCYTE PHARMA INC ;AZIMZAI YALDA (US); CORLEY NEIL C (US); REDDY R) 9 March 2000 (2000-03-09) see SEQ ID No. 28: 98.1% identity in SEQ ID No. 28: 1276bp overlap with SEQ ID 3; 89,5% identity in 516bp overlap with SEQ ID No. 40; 98,0% identity in 1276bp overlap with SEQ ID No. 43; 98,1% identity in 1276bp overlap with SEQ ID No. 44; 67,0% identity in 1268bp overlap SEQ ID NO. 4 and SEQ ID No. 28; 67,0% identity in 1268bp overlap with SEQ ID No. 15; 67,0% identity in 1268bp overlap with SEQ ID No. 16;	1,2,8, 22,23

-/-

INTERNATIONAL SEARCH REPORT

Inter. Appl. No.
PCT/US 99/23519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WILLIAMS, M.E. ET AL.: "Structure and functional expression of alpha 1, alpha2, and beta subunits of a novel human neuronal calcium channel subtype" NEURON, vol. 8, January 1992 (1992-01), pages 71-84, XP000886416 see Figure 3; last paragraph, second column, page 84</p>	1
A	<p>WALKER, D. AND DE WAARD, M.: "Subunit interaction sites in voltage-dependent Ca²⁺ channels: role in channel function" TRENDS IN NEUROSCIENCES, vol. 21, no. 4, 1998, XP000887176 cited in the application see the whole document</p>	1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/23519

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 19, 20, 31-33
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-26, 31-34 (all partially)

subject-matter related to calcium channel alpha 2 delta C protein: claims 1-7, 15, 16, 19, 20, 21 as far as they relate to SEQ ID No. 3; claims 8-11 and 17, 18 as far as they relate to SEQ ID No. 5; claims 12-14 and 31-33 as far as they relate to "alpha 2 delta C"; claims 22-26 as far as they relate to SEQ ID Nos. 11, 14, 40, 41, 43, 44, 47-49; claims 34 as far as it is related to accession nos. from AU022914.1 to AI051759.1 and SEQ ID Nos. 3, 5, 9-14, 36-41, 43, 44, 47

2. Claims: 1-26 (all partially), 27-30, 31-34 (all partially)

subject-matter related to calcium channel alpha 2 delta D protein: claims 1-7, 15, 16, 19, 20, 21 as far as they relate to SEQ ID No. 4; claims 8-11 and 17, 18 as far as they relate to SEQ ID No. 6; claims 12-14 and 31-33 as far as they relate to "alpha 2 delta D"; claims 22-26 as far as they relate to SEQ ID Nos. 15, 16, 21-24; claim 34 as far as it is related to accession nos. from T70594.1 to AA001473.1 and SEQ ID Nos. 4, 6, 15, 16, 18-24, 42, 45, 46, 48, 49.

3. Claims: 22-26, 34

subject-matter related to calcium channel alpha 2 delta B protein: claims 22-26 as far as they relate to SEQ ID Nos. 31-35; claim 34 as far as it relates to accession no. AF040709.1 and accession nos. from T80372.1 to Z84492.1 as well as SEQ ID Nos. 1, 2, 7, 8, 25-35.

4. Claim : 34 (partially)

method of using polynucleotides sequences to identify the binding potential of polynucleotide sequences to gabapentin: claim 34 as far as it is related to accession nos. not mentioned before

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 33 directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Although claims 19, 20, 31, 32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 19, 20, 31-33

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 99/23519

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9504822 A	16-02-1995	US 5874236 A	23-02-1999
		AU 3390499 A	19-08-1999
		AU 707793 B	22-07-1999
		AU 7632294 A	28-02-1995
		EP 0716695 A	19-06-1996
		GB 2284814 A,B	21-06-1995
		JP 9509041 T	16-09-1997
WO 9811131 A	19-03-1998	US 6040436 A	21-03-2000
		AU 4343097 A	02-04-1998
WO 0012711 A	09-03-2000	AU 6137699 A	21-03-2000